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The work depicted in this thesis, explores the use of drug loaded porous silicon nanoparticles (pSiNP) 
targeted to dendritic cells both in vitro and in vivo. Paper one explores the in vitro application of rapamycin 
loaded, DC-SIGN pSiNP to induces a maturation resistant, tolerogenic state within human monocyte 
derived DC. Furthermore, it explores the poor stimulatory ability of these tolerogenic DC within an 
allogeneic immune system. The study concluded that nanoparticles functionalised with DC-SIGN 
antibody, were capable of tracking to human monocyte derived DC expeditiously compared to their isotype 
counterparts. DC-SIGN pSiNP were also able to release their payload and induce a tolerogenic state in DC 
in vitro. Paper two develops the work from paper one exploring the in vivo tracking capability of the 
nanoparticle within both murine and non-human primate animal models. Within mice, the functionalisation 
of the pSiNP with antibodies permitting targeting to DC (CD11c receptor) significantly enhanced their 
tracking abilities to splenic DC populations, compared to isotype pSiNP. Within both murine and non-
human primate animal models, a serendipitous discovery was the enhanced kidney tracking abilities of the 
DC targeting pSiNP. This opens the door for the development of potentially new drug delivery methods 
more localised to the kidneys. Following in vivo tracking experiments, paper two explored the ability of 
drug and peptide loaded nanoparticle to enhance regulatory T-cell populations in vivo by targeting DC. It 
was concluded that the CD11c pSiNP were capable of significantly increasing the number of splenic 
regulatory T-cells when compared to the control animals, which did not receive pSiNP. These two papers 
identify a novel strategy for promoting drug delivery to a scarce cell population and the ability to promote 
regulatory T-cell generation in vivo without ex vivo modification of DC, which is more commonly seen 
today. The results show promise for future development of an enhanced drug delivery method to modify 
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In recent studies, exploring alternative methods facilitating the transport of chemotherapeutics, genetic 
material and immune modulators has sparked the interest of many scientists. This has given rise to the 
emerging field of nanomedicine, aimed at exploring the use of nanoparticles (NP) for a range of different 
applications. Nanoparticles offer a unique medium, as the can be composed of a range of different 
materials, benefiting a range of application due to their customisability in size, shape and surface 
modifications, termed functionalisation. The functionalisation of particles with peptides, antibodies or 
genomic fragments, allows for specific targeting and directed NP content release both in vitro and in vivo. 
This can provide beneficial therapy to cancer patients receiving conventional chemotherapy. It also offers 
the medical professional and alternative way to treat their patients. The production of NP which have the 
ability to home in and target cancer cells specifically, allowing for localised release of chemotherapeutic 
drugs, decreases the amount of toxic drugs that may otherwise be administered to the patient (1, 2). This 
would reduce damage to healthy tissue and organs, increasing the well-being and quality of life of the 
patient. Research has shown that NP loaded with immune modulators possess the ability to enhance or 
suppress the immune system (3-7). As chronic administration of immunosuppression can lead to 
opportunistic infections, reactivation of latent pathogens and the development of tumours (8-10), this 
treatment also has particular benefit to organ transplant recipients. 
This review will explore some of the commonly studied nanoparticles and their applications in drug 
delivery, cancer therapy and imaging. There will be a focus on transplant immunotherapy and how 
nanoparticles could be used for the induction of immunological tolerance. Some of the current limitations 
that exist within the field of nanomedicine, which may represent current roadblocks for the translation of 
nanoparticles into more commonly used clinical settings will also be discussed. 
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Nanoparticles 
Nanoparticles are defined as, ultra-fine, microscopic structures a billionth of a meter in size. Liposomes 
were the first identified composite for NP experimentation. First described as the cellular membrane in 
1965 (11), liposomes have developed into a platform for gene and drug delivery. The particle can be 
composed of a mono- or bilayer structures of self-assembling lipids (12). Liposomes offer several 
advantages for NP therapy, including their ability to encapsulate molecules, their tuneable biodegradability 
and biocompatibility (13). Their unique characteristics make them suitable as transfection reagents, 
transferring genetic materials into cells, promoted by lipofection, which utilised charge interactions 
between the cationic lipids to aggregate with the anionic material (13). Liposomes have been used as 
carriers for therapeutics, as their composition allows seamless interaction with the cellular lipid bilayer 
(11). The hydrophilic core and hydrophobic shell also offers a unique surface for the entrapment of 
different drug compounds. NP can undergo surface modifications, which can enhance or promote new 
functions of the NP. Polyethylene glycol (PEG) is a commonly used compound due to its biocompatibility 
with liposomes. PEG can be used to extend the half-life and stability of liposomes in vivo (12). Currently, 
there are 15 liposome-drug based therapies approved for clinical use (14). 
Polymeric NP are derived from biocompatible and biodegradable natural polymers and have been 
comprehensively investigated as carriers of therapeutics (15). Polymeric NP are composed by block 
copolymer controlled polymerisations. The process involves control NP chain extension with monomers 
which permits a multifunction, multi-composite nanoparticle product. Once the copolymer is formed, they 
undergo spontaneous assembly into a core-shell micelle structure within an aqueous environment (16). 
Some of the most commonly used natural polymers include: chitosan, gelatin and sodium alginate (17-19). 
However, polymeric NP often respond to changes in pH by decreased stability (20) and because of this, 
synthetic polymers have been developed to overcome this limitation. Poly(D, L-Lactide), poly(lactide-co-
glycolide) (PLA) or poly(lactic acid) are among the most commonly used. Although capable of overcoming 
stability issues, they increase NP biotoxicity. Polymeric NP have been used for the encapsulation of 
hydrophilic and hydrophobic small drugs and proteins and nucleic acid macromolecules (21). 
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Incorporating targeting ligands on the NP surface have also shown to increase cellular uptake and enhanced 
therapeutic outcomes. 
Dendrimers are a subset of polymeric NP, defined by the branching ‘tree-like’ chemical structure. Again, 
these particles can be comprised of both natural and synthetic monomers such as amino acids, sugars and 
nucleotide (22). The dendrimers have a unique core which is comprised of several branched interior layers. 
This unique structure allows for the modifications of NP shape, size and stability (23, 24). Dendrimer 
surface modification allow for applications within medical imaging via chemical functional group 
modification (25). 
Albumin-bound NP, abraxan, is a 130 nm complex bound to chemotherapeutic paclitaxel. It was clinically 
approved in 2005 for the treatment of breast cancer (26). Albumin based NP therapies exploit the natural, 
non-covalent, reversible binding ability of albumin to hydrophobic molecules. This mechanism bypasses 
the solvent-based toxicity for certain therapeutics (27). The albumin coating on the drug offers a type of 
drug functionalisation, as endothelial cells will concentrate the drug via albimun binding protein (gp60)-
mediated transport, as well as SPARC (albumin secreted protein acidic and rich in cysteine), which is 
overexpressed in some cancers (28). 
Quantum dots (QD) are unique particles which demonstrate side-dependant optical properties. Usually 
comprised of cadmium selenide (CdSe) and zinc selenide (ZnSe) core and shell respectively, these NP emit 
bright colours within a narrow wavelength band upon excitation. This unique property, along with their 
decreased photobleaching, long half-life and efficiency, gives them a significant advantage for diagnostic 
use, over the conventionally used organic fluorescent dyes for optical imaging, cell labelling and 
biomolecule tracking (29-31). 
Iron oxide NP have been extensively studied as imaging agents, exploiting their superparamagnetic 
characteristic. Superparamagnetic iron oxide NP (SPION) can be composed of an iron oxide core, most 
commonly magnetite (Fe3O4) coated with dextran, chitosan or alginate (32-34). SPION have been used 
with T2 weighted magnetic resonance (MR) as contrast agents due to the ability to manipulate the core 
size, offering a size-dependant magnetic field strength. SPION have been especially useful in the 
monitoring of atherosclerosis (35, 36). Conventionally, gadolinium-chelated contrast agents are used for 
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MRI imaging. Ferumoxide and ferucarbotran are two clinically approved SPION  based MRI imaging 
reagents (37), which have shown reduced toxic side effects whilst also having increased image sensitivity 
and specificity (38).  In vivo, SPION are metabolised to iron which can be stored as ferritin and aid with 
erythropoiesis (38). SPION have also been functionalised with targeting ligands, allowing them to be use 
for both passive and active imaging agents (39). 
Gold NP can be modified to alter size, shape, optical and chemical properties, display biocompatibility and 
permit surface modification (33).  Gold interacts uniquely with free electrons within molecules and because 
of this, gold NP can enhance light absorption, scattering and fluorescence (40). These unique characteristics 
allow gold NP to be used for biochemical sensing, imaging, diagnostics and therapeutic applications. 
Colourmetric arrays, used to identify toxic industrial chemicals and surface-enhanced Ramen spectroscopy 
(SERS), commonly used to identify low abundance biomolecules, can be significantly enhanced when used 
in conjunction with gold NP (41). 
Mesoporous Silica NP (MSN) were first reported in 2001 as a material for drug delivery (42). MSN have 
textural properties that make them excellent drug carriers, as their loading capacity and surface area is 
greatly increased, further enhanced by surface pores. This property of MSN can also be controlled during 
the manufacturing process by altering the functionalization of silanol groups, altering drug diffusion 
kinetics (43, 44). MSN have been unitised in various imaging applications by loading the particles pore 
with quantum dots or fluorescent dyes (45, 46). Surface modifications of MSN have been explored as an 
active target mechanism. NP have been coated with cancer specific targeting drugs and have displayed 
increased cancer cytotoxicity compared to controls (47). 
Porous Silicon NP (pSiNP) offer an alternative to the above. Elemental silicon can be electrochemically 
etched to produces particles of varying size, shape and porosity. pSiNP display larger surface area to size 
characteristic as well as the ability to chemically modify the surface. This allows for loading with a huge 
variety of drugs, macromolecules and genomic materials, giving the pSiNP a myriad of applications. pSiNP 
are also highly biodegradable to non-toxic silicic acid, which is renally excreted (48). A majority of current 
research exploring nanoparticles as an improved therapy, study their use within a cancer setting. The role 
that nanoparticles could play within the suppression of the immune system, prevention transplant 
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rejections, is highly underrepresented.  The applications of these nanoparticles will be explored further in 
this review. A summary of some common nanoparticles and their use can be seen in table 1 and figure 1. 
Figure 1. Cartoon depiction of the various nanoparticle compositions. 
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Table 1. Brief Summary of Nanoparticle Targets and Functionalisations 
Nanoparticle Functionalisation Target/Use Reference 
liposomes 
Amiloride hydrochloride Cystic Fibrosis (49) 
Budesonide Asthma (50) 
Doxorubicin + Verapamil MDR-Leukaemia (51) 
Insulin Diabetes (52) 
IL-2 Lung Cancer (53) 
Irinotecan + Cisplatin Small-Cell Lung Cancer (54) 
Ketotifen Asthma (55) 
siRNA + Doxorubicin MDR-Breast Cancer (56) 
Tobramycin Pulmonary Infections (57) 
Vincrisine Brain Cancer (58) 
VEGF Gene Pulmonary Hypertension (59) 
Albumin Paclitaxel Breast Cancer (27) 
Polymeric 
RBITC hAGP and hRGF (60) 
Doxorubicin ICAM-1 (61) 
Folate HEC-1A Cancer Cells (62) 
BSA MCF-10A neo T-cells (63) 
Dendrimers 
Boron Neuron Capture Technology (64) 
Doxorubicin Colon Carcinoma (65) 
Efavirenz HIV (66) 
Phosphorus HIV-1 (67) 
Lamivudine HIV (68) 
siRNA Lymphocytes (69) 
G3. 5 PAMAM SN38 Hepatic Colorectal Cancer (70) 
Sulphate Oligosaccharide HIV (71) 
Iron Oxide 
Lauric Acid SPION Breast Cancer (72) 
Maghemite MRI (73) 
Folic Acid MRI (74) 
EGF Brain Tumour (75) 
Poly-Dopamine Stem Cells (76) 
Quantum Dots 
5-Fluorouracil Breast Cancer (77) 
Doxorubicin Ovarian Cancer (78) 
Saquinavir HIV-1 (79) 
Gold 
Methotrexate Lung Cancer (80) 
6-mercaptopurine Leukaemia (81) 
Tamoxifen-poly(ethylene glycol)-thiol Breast Cancer (82) 
Rhodamine 6G Raman Imaging (41) 
Mesoporous 
Silica 
Folic Acid Pancreatic Cancer (83) 
Camptothecin Pancreatic Cancer (83) 
Doxorubicin + Bcl-2 siRNA HeLa Cells (84) 
Galactose Cancer (85) 
γ-Secretase Inhibitor Notch Therapy (86) 
Polyethyleneimine Cancer (87) 
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Allo Immunity 
Patients receiving allogeneic organs are required to take life-long immunosuppressive medications to 
prevent the development of graft versus host disease (GVHD) and organ rejection. The allo-immune 
response within a transplant patient is initiated by foreign antigens expressed on the donor organ or via 
passenger leukocytes. Without ‘proper intervention’, the immune system will begin to target the cells 
expressing foreign antigens, inevitably leading to decreased graft function and organ rejection. Patients 
require constant treatment to combat organ rejection and often necessitating secondary transplants, at 
immense cost on both a personal and financial level. Mechanistically, allo-immunity occurs when there is 
a genetic mismatch existing between the donor and patient genes, coding for the major histocompatibility 
complex (MHC) proteins (88). 
There are two main forms of the MHC proteins relevant in transplantation, class I and class II (Figure 2). 
These proteins are responsible for the presentation of peptide fragments on the cell surface allowing for T-
cells interaction. MHC class I can be further subdivided into human leukocyte antigens (HLA) A, B and C 
(89). HLAs are located on the short arm of chromosome 6, each parent providing a haplotype in Mendelian 
codominant inheritance to their progeny (90). HLA-A, B and C are expressed on all nucleated cells within 
the body and contain a polymorphic heavy α chain and non-polymorphic light β2 chain. Endogenous 
peptide fragments, approximately 9-11 amino acids, are expressed on HLA class I to cytotoxic CD8+ T-
lymphocytes (CTL). High affinity interactions with the T-cell receptor (TCR) expressed on CTL and the 
epitope within the MHC class I molecules trigger programmed death signals inducing apoptosis. This 
process is the initiation of cellular immunity and is the primary means that our body uses to combat 
intracellular pathogens such as bacteria and viruses (91). Cross presentation can also occur with CD8+ T-
cells. This is where extracellular antigen are presented on the surface of MHC class I proteins to naïve 
CTL. Strong TCR-MHC interactions added by costimulatory proteins CD28 on the T-cells and B7 
receptors (CD80/CD86) on the antigen presenting cell (APC), lead to activation of the naïve CTL. 
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MHC class II can be subdivided into HLA-DR, DQ and DP and are primarily expressed on the surface of 
APC, such as macrophages, B cells and DC (90). Class II HLA contain both polymorphic α and β chains. 
Phagocytosis of extracellular debris, by APC undergoes processing and epitope presentation, usually 
between 12-28 amino acids. If strong interactions occur between the CD4+ TCR receptors on naïve T-
helper cells followed by co-stimulatory signalling by B7 and CD40 on APC interacting with CD28 and 
CD40L on T-cells, activation and clonal expansion of antigen specific CD4+ lymphocyte will occur (92-
94). The degree of HLA mismatch between donor and recipient is a determining factors of the degree of 
chronic organ rejection and graft loss (95). Traditionally, HLA A, B and DR are commonly typed and 
matched before kidney or pancreas transplants, with mismatches in HLA-DR being associated with poor 
patient-graft outcomes (96-98). 
Figure 2. Dendritic cell (DC)– T-cell interaction. MHC Class I interacts with CD8+ T-cells via the T-cell 
receptor (TCR) to present endogenous peptides leading to cytotoxic activation of the lymphocyte. MHC 
Class II is expressed on professional APC cells, presenting exogenous peptides to CD4+ T-cell. Co-
stimulatory markers CD40-CD40L provide signal 2 for complete lymphocyte activation. MHC Class I is 
expressed on all nucleated cells. Cytotoxic T-cells (CTL) interact with MHC Class I along with co-
stimulatory markers CD80/CD86-CD28 promoting CTL activation and proliferation. Image adapted from 
Thaiss et al. (99) 
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In 1977 a review published by Lafferty et al. described the activation of allogeneic T-cells requiring three 
complimentary signals (100). More recent studies have expended on this hypothesis to identify some of 
the key mechanisms involved within the three signals. Signal one occurs during the interactions of the 
antigen presented on the MHC molecule to the TCR-CD3 complex. Signal two involves interactions 
between the costimulatory molecules. Several secondary signalling pathways have been described, 
however the best studied involves CD28-B7 and CD40L-CD40. Upon successful signals 1 and 2, the 
calcium-calcinurin, RAS-mitogen activated protein kinase and IKK-nuclear factor κB (NF-κB) pathways 
are activated. These pathways lead to the activation of transcription factors: nuclear factor of activated T-
cells (NFAT), activation protein-1 (AP-1) and NF-κB respectively (101-103). T-cell also provide tertiary 
signals from secretion of IL-2 and IL-15 as well as upregulate CD25 (IL-2R) and CD40L (104-106), 
augmenting the cytokine environment around the interacting cells (107, 108) (Figure 3). IL-2 and IL-15 
provide growth signals to the T-cells and NK cells via the mammalian target of rapamycin (mTOR), 
triggering T-cell cycle and proliferation (109, 110) . The T-cells will undergo clonal expansion coinciding 
with a burst of IL-2 release, promoting effector T-cell and CD8+ T-cell mediated cytotoxicity. 
Figure 3. Three signals required for T-lymphocyte activations, leads to intracellular cascades activating 
transcription factors NFAT, AP-1 and NF-κB. Cytokine signalling via IL-2 activates mTOR pathway, 
leading to cell cycling and cell proliferation. 
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T-cell also respond to negative signals to decrease cellular activity. Program death ligands (PD-
L), are transmembrane proteins part of the B7 receptor superfamily, expressed on APC and are 
responsible for immune system suppression. Two major types of PD-L exist, PD-L1 and PD-L2, 
which are capable of binding to receptor programmed cell death 1 (PD-1); on the surface of T- 
and B-cells. Activation of PD-1 inhibits T-cell proliferation, by inhibiting ζ-chain associated 
protein kinase 70 (ZAP-70) phosphorylation and T-cell surface glycoprotein CD3ζ reducing T-
cell receptor (TCR) mediated activation. (111). This results in downstream inactivation of 
transcription factors NF-κB and AP-1 via decrease phosphorylation of protein kinase C theta’s 
(PKC-θ) activation loop (112) (Figure 4). 
Figure 4. Programmed cell death (PD)-1 expression on T-lymphocytes inhibits T-cell receptor 
(TCR) signalling via tyrosine phosphatase, SHP-2. PD-1 activation by its ligands, PD-L1 or PD-
L2, recruit SHP-2, promoting dephosphorylation of Zeta-chain-associated protein kinase 70 
(Zap70). Zap70 dephosphorylation inhibits T-cell activation via CD3 (signal 1), preventing 
complete lymphocyte activation. Image is adapted from Okazaki et al. (113) 
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High affinity docking to the epitope presented on MHC class II molecules expressed on the APC resulting 
in the priming of the naïve T-helper cells,  results in differentiation of the T-helper cells into several 
different subsets, including: memory T-cells, effector T-cells and T-regulatory cells (Tregs). The 
determinant for the differentiated subset is governed by the degree of co-stimulation and balance of 
cytokines expressed at those loci (114). Each population of CD4+ T-helper cells have a unique set of 
functions, which will be discussed below. 
Central memory T-cells are CD45RO+ and expressed C-C chemokine receptor type 7 (CCR7) and CD62L, 
responsible for extravasation and migration to secondary lymphoid organs. The role of a memory T-cell is 
to respond to their cognate antigen upon repeat exposure. When exposed to their specific antigen, memory 
T-cells upregulate CD40L to a greater extent, resulting in more efficient activation of B-cells and DC and 
secretion of large quantities of IL-2 (115, 116). 
Effector T-helper cells can differentiate into three main subtypes, Th1, Th2 and Th17 (117). Th1 cells are 
part of the cell mediated immunity and provide defence against intracellular micro-organisms, particularly 
in resistance to mycobacterial infections. The cytokine products of Th1 cells are IL-2, lymphotoxin α (LTα) 
and Interferon γ (IFN-γ) (118). IFN-γ secreted by these cells plays a role in activating macrophages 
increasing microbicide activity and IL-2 is important for the establishment of CD4+ T-cell memory and 
stimulation of cytotoxic CD8+ T-cell proliferation.  
Th2 cells contribute to humoral immunity, protecting us against extracellular pathogens. Secretions from 
these cells include IL-4, IL-5, IL-9, IL-10, IL-13, IL-25 and amphiregulin. IL-4 contributes to the positive 
feedback for Th2 cell differentiation and class switching in B cells (119, 120). Activated B-cells that interact 
with Th2 cells via CD40L or particular cytokines, such as IL-4, promote immunoglobulin (Ig) switching 
to produce IgG, IgE and IgA antibodies. IgE are more prominent within a hypersensitivity type I reactions 
(121). IgE production by B-cells, promotes the antibody uptake by high-affinity IgE receptor, FcεRI, on 
basophils and mast cells. Upon FcεRI cross-linking, the cells will degranulation, resulting in the secretion 
of histamine, serotonin, IL-4, IL-13 and tumour necrosis factor α (TNF-α) resulting in an inflammatory 
response. IL-5 secretions from Th2 cells are important for the recruitment of eosinophil granulocytes (122). 
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IL-10 plays a role in suppressing Th1 cell proliferation and has been shown to suppress the function of 
dendritic cells (123).  
Th17 plays an important role in the recruitment of neutrophils and macrophages to infected tissue, 
mediating a pro-inflammatory response. This cell subset secrets IL-17 which binds receptor IL-17 receptor 
A (IL-17RA), a receptor widely expressed on mesenchymal cells, such as endothelial cells, epithelial cells 
and fibroblasts (124). The binding of IL-17 activates transcription factor NF-κB and mitogen-activated 
protein kinase (MAPK) pathways (125, 126). A summary of the T-helper cells can be seen in figure 5. 
Figure 5. T-helper cell differentiation from CD4+ naïve T-cells. CD4+ T-cell activation by 
an APC with the addition of co-stimulation through CD28 and/or cytokines can lead to the 
differentiation into three main subsets of T-helper cells, Th1, Th2 and Th17. Th1 cells are 
major secretors of INF-γ, Th2 mainly secrete IL-4 and IL-5 and Th17 respond to IL-23 and 
secrete IL-17 cytokines. Image adapted from Dong et al.(127). 
Allo-recognition - Transplant rejection 
Within a transplant setting, a patient can become sensitise to the donor HLA antigens, contributing to organ 
rejection. There are two main mechanisms by which this occurs, the direct and indirect pathways. The 
direct pathway involves the donor APC interacting directly with the recipients T-cells, whereas the indirect 
pathway is when the recipient APC presents an allo-peptide to a recipient T-cells (Figure 6). Activation 
via the direct pathway is clinically very important immediately post-transplant. If appropriate 
immunosuppression is not provided, a potent allo-response would follow resulting in acute cellular 
rejection. The indirect pathway is more responsible for the delayed immune reaction. Discrete populations 
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of effector T-cells and T-helper cells promote immunoglobulin class switching, memory B-cell and plasma 
cell production, leading to the development of the humoral immunity and production of donor specific 
antibodies (DSA) directed towards donor HLA. 
Figure 6. Direct and indirect pathways of allorecognition 
which contribute to allogeneic graft rejection. The direct 
pathway involves interactions of donor DC with recipient 
CD4+ and CD8+ T-cells. Indirect allorecognition is the 
processing and presentation of donor MHC via recipient 
APC. Image is adapted from Janeway’s immunobiology 
(121). 
Dendritic Cells – The Professional APC 
Within humans, there are three major DC population 
lineages, myeloid, plasmacytoid and monocyte-related 
(128). Myeloid dendritic cells originate from CD34+ 
myeloid haematopoietic stem cells within the bone marrow. 
These cells can differentiate into two lineages; CD14+ 
CD11c+ monocytes (129) and lineage negative (LINneg) 
CD11c- IL3Rα+ precursor DC (130). Exposure to IL-2, IL-4 and granulocyte/macrophage colony 
stimulating factor (GM-CFS) induces the differentiation of the monocytes into immature DC (131). 
Dendritic cells are very rare, making up only 0.6-1.7% of the peripheral blood mononuclear cells (PBMC) 
within a human (132). Due to their rarity, DC are obtained by culturing monocytes with GM-CSF and IL-
4 for in vitro and in vivo experimentation. The exact concentration of these cytokines vary within different 
laboratory centres and because of this the monocyte derive iDC can have a variances in levels of surface 
molecule expression. The consensus is that iDC have low expression of costimulatory markers CD40, 
CD80, CD86 and CD83 with high expression of MHC class II molecules. Human monocyte derived and 
21 
myeloid DC lineages express a unique receptor Dendritic Cell-Specific Intercellular adhesion molecule-3-
Grabbing Non-integrin (DC-SIGN, CD209). DC-SIGN has been studied mainly because it is the binding 
receptor of both Hepatitis C and human immunodeficiency virus (HIV) (133-135). However, because of 
its unique expression it provides an optimal target for DC specific therapy. CD11c is another uniquely and 
highly expressed surface receptor found on dendritic cells, fitting the criterial as an alternative targeted for 
nanoparticle tracking, especially within a murine model. Mice possess several different DC subtypes within 
the myeloid and plasmacytoid lineages. The CD11c integrin, alpha X (ITGAX)+, is expressed primarily on 
the murine conventional DC lineages, CD11c (High) CD4+ CD8a-, CD4- CD8a+ and CD4- CD8a- DC 
subsets (136). Murine CD11c offers a more analogous targeting receptor to human DC-SIGN compared to 
murine DC-SIGN. Comparatively, murine DC-SIGN in expressed on only the CD4+ and double negative 
myeloid DC lineages as well as  plasmacytoid pre-DC (137), whereas murine CD11c is expressed on all 
the myeloid DC subsets and not plasmacytoid DC, similar to human DC-SIGN. Exploring the difference 
of nanoparticles targeting both CD11c and DC-SIGN could be highly beneficial in identifying an optimal 
receptor for myeloid DC uptake of nanocarriers for localised drug delivery. 
Differentiation of monocytes into immature DC causes migration of the DC into the blood and to lymphoid 
tissue where they begin to phagocytose debris from apoptotic cells and present their antigens to T-cells. 
During a bacterial infection or the damaging of tissue due to transplantations, inflammatory mediators, 
such as lipopolysaccharides (LPS) or TNF-α respectively, are released. These mediators then act on 
immature DC to induce maturation into mature DC (mDCs). 
Mature DC express high levels of co-stimulatory markers CD40, CD80 and CD86 as well as adhesion 
molecules ICAM1 (CD54) and CD58 and CCR7 chemokine receptor (92-94). Mature DC have decreased 
endocytic and phagocytic abilities and possess high levels of MHC II, increasing their antigen processing 
and presenting capacity. The phenotype of an mDC allows them to interact and activate naïve and memory 
CD4+ and CD8+ T-cells, mounting an immune response that can target specific pathogens or initiate 
allograft rejection. 
Plasmacytoid DC (pDC) are among another subset of DC, characterised by lineage negative MHC II+ 
CD303 (BDCA-2)+ surface expression. In an immature state, pDC are tolerogenic, where upon activation 
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can be either stimulatory or suppressive, which is dependent on the localised cytokine environment. pDC 
are known for their ability to secrete large amounts of Type I interferons (IFNs)-α and IFN-β, especially 
in response to viral infections. 
Dendritic Cell Therapy for Cancer 
As DC are capable of mounting an immune response directed towards single antigens, they have been 
explored as a novel form of cancer therapeutically termed, DC vaccines. Matured,  HLA-A2 binding 
MUC1 pulsed human monocyte derived DC were used in a phase I trails in patients with metastiatic renal 
cell carcimona (RCC) (138). The aim was to use autologous matured DC to stimulate CD4+ lymphocyte 
activation, reversing immune system senescence which is offen associated with cancer. During trials a 
group of patients receiving subcutanious injections of DC combanatorially with low-dose IL-2 
demonstated tumour regression whilst also capable of producing a MUC1 peptide-specific T-cell response. 
Phase I/II trials were conducted using using Wilms’ tumor1 protein (WT1) preconditioned DC as a cancer 
vaccine in individuals with acute myeloid leukaemia. DC administration was shown to induce complete 
remission in several patients who were in partial remission after chemotherapy (139). Furthermore, WT1 
specific IFN-γ secreting CD8+ T-cells were observed in vaccinated patients. The fussion of multiple 
myeloma (MM) cells to DC was also investigated as a novel cancer vaccine in patients who had received 
autologous stem cell transplantation (ASCT) treatement. A majority of the patients receiving the vaccine 
responded well to the treatement, with a reduction in their disease whilst also displaying both CD4+ and 
CD8+ myelma specific T-cell responses after ASCT (140). 
Dendritic Cells and the Induction of Tolerance 
Without DC-T-cell co-stimulatory interactions there is insufficient stimulation to activate T-cells but 
instead T-cell anergy is induced (114). DC which lack the necessary co-stimulatory molecules required for 
complete lymphocyte activation, not only have the ability to induce T-cell anergy but also promote the 
production of regulatory T-cells. Induced Treg (iTregs), differentiate in peripheral lymphoid tissues under 
tolerogenic conditions (141). The in vivo expansion of this cell type, utilising ex vivo modified DC has 
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been explored within several studies and clinical trials, in order to promote immunological tolerance within 
transplant recipients. 
The important role dendritic cells play within immune system was first recognised by Steinman et al. in 
1983 but remarkable advances into the study of DC and their ability to induce tolerance were not 
thoroughly explored until the beginning of the 21st century (142, 143).  The most common method for the 
production of tol-DC is culturing phenotypically immature DC with IL-10, TGFβ, hepatocyte growth factor 
and vasoactive intestinal peptide. Under these conditions the cells express low levels of MHC complexes, 
limited co-stimulatory molecules and decreased pro-inflammatory cytokines, allowing them to induce T-
cell apoptosis and anergy (144). 
DC have shown promising abilities to prevent allograft rejection. Morelli et al. and Wang et al., (145, 146) 
experimented with intravenously infusing early apoptotic donor splenocytes in quiescent, prospective 
murine heart allograft recipients a week prior to transplantation and showed prolonged graft survival. 
Combining this treatment with a single, simultaneous injection of anti-CD40L monoclonal antibodies 
(mAb), indefinitely prolonged graft survival. A more recent study by Jian et al., investigated the use of 
long non-coding RNA induced tol-DC to significantly prolong heart allograft survival. This study 
highlights the potential benefit of utilising genomic material as a method for tolerance induction (147). 
Tol-DC generated from vitamin D3 and IL-10 have been intravenously infused into rhesus macaque kidney 
allograft models. Preliminary DC infusions, concurrently with B7-CD28 co-stimulation locker (CTLA4Ig), 
demonstrated increase graft survival by approximately 3-fold whilst also regulating donor reacting memory 
CD95+ T-cells (148).  The European consortium, the ONE Study is currently evaluating the safety and 
plausibility of cell therapy using autologous Tol-DC in living-donor kidney transplantation by phase I/II 
clinical trial (149). In 2016, Thomson et al., proposed to perform phase I/II safety studies exploring the 




A common and well-studied immunosuppressive medication used for the prevention of organ rejection is 
rapamycin (Sirolimus). Rapamycin is a macrocyclic lactone product of Streptomyces hygroscopicus that 
causes disruption of the mammalian target of rapamycin (mTOR) pathway, inhibiting interleukin-2 (IL-2) 
signalling, suppressing B and T-cell activation (47, 151-154). Rapamycin is a potent inducer of tolerance 
in dendritic cells (DC), one of the most important immune cells with our body. DC possess the dichotomous 
function of immunostimulation and immunosuppression. They are the most potent of our antigen 
presenting cells (APC) (155) and are the key contributors to the development of graft versus host disease 
(GVHD), due to their specialised ability to process and present foreign peptides to T-cells. However, 
preconditioning DC with rapamycin, producing tolerogenic DC (tol-DC), promotes T-cell anergy and 
immunological tolerance (156-158). The ability to produce a functionalised NP, modified to express DC 
targeting antibody and secrete rapamycin, would provide a strong basis for the use of nanoparticles as a 
novel immunosuppressive therapy. In vivo, this could lead to prevention of allograft rejection in those who 
receive genetically mismatched donor organs and alleviate the necessity for chronic, systemic immune 
system suppression.  Combining the interchangeable surface molecules and the ability to load a variety of 
drug cocktails or peptides, the use of nanoparticles for the treatment of multiple diseases is highly possible. 
Although there are several compounds capable of inducing tol-DC, including vitamin D3, aspirin and even 
semen, rapamycin is of great interest because of its clinical relevance within the transplantation sector 
(159-161). Rapamycin is an immunophilin ligand and a macrocyclic-triene antibiotic produced by 
Streptomyces hygroscopicus, first described by Sehgal et al. (152), extracted from the mycelium within 
fungus identified on Easter Island. The drug binds the immunophilin FKBP-12 and acts as an inhibitor of 
RAPTOR-bound mTOR, preventing serine/threonine kinase autophosphorylation (162). mTOR inhibition 
causes the cell cycle to arrest at G1 and S phases and temporary inhibition of 4E-BP1, preventing growth 
factor driven proliferation of T-cells and other haematopoietic and non-haematopoietic cells and 
suppressed mRNA translation, effecting both secondary and tertiary signalling of T-cell activation (163, 
164) (figure 7). 
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Figure 7. Rapamycin bind FKPB12, inhibiting mTOR1 and downstream activation of 4E-BP1 and S6K1. 
Rapamycin initiates cell cycle to arrest at G1 and S phases and the suppression of mRNA synthesis. Image 
is adapted from Garcia et al. (165) 
Animal studies performed by Molano et al. on non-obese diabetic (NOD) mice receiving allogenic islet 
grafts and treated with rapamycin post transplantation, showed that rapamycin was able to prevent rejection 
and auto-immunity and hence prolong graft survival and insulin independence (166). It was reported by 
Toso et al. that converting from a cyclosporine-mycophenolate (MMF) combination to the Edmonton 
immunosuppressant regimen (Sirolimus and Tacrolimus), was highly beneficial to patients with borderline 
islet graft function (167). The extensive use of rapamycin has sparked debate over its efficacy and safety 
(168). 
The detrimental effects of rapamycin have been well documents within pancreatic islet transplant settings. 
Pancreatic β-cell viability (169), glucose stimulate insulin release, pancreatic and duodenal homeobox 1 
(PDX-1) and glucose transporter 2 (GLUT2) gene expression (170) were seen to decrease in vitro, when 
cultured with rapamycin. In vivo, rapamycin has been seen to impede islet cell engraftment and β-cell 
function (170, 171). Islet transplant animal models on rapamycin or rapamycin-tacrolimus combinatorial 
regimens demonstrated counterproductive effects, leading to the development of insulinemia, ergo 
hyperglycaemia within the animals. These results demonstrate that rapamycin has an effect on insulin 
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secretion pathways or can induce insulin hyporesponsiveness (172, 173). Studies have contradictory 
observations regarding the effects of rapamycin on β-cells function. This is most likely attributed to 
interspecific variation in animal models resulting in physiologically different responses to rapamycin 
treatments (174). Detrimental effects of rapamycin within humans have also been reported, however less 
extensively, in human islet cultures (175, 176). Studies which have demonstrated deleterious effects due 
to rapamycin, utilise extremely high concentrations, between 10-50 times higher than the clinically relevant 
dosage (175, 177-179). Studies by Laugharne et al., Zhang et al. and Bussiere et al., performed on rodent 
models have challenged the view of rapamycin’s deleterious effects (169-171). 
Rapamycin is not only a favourable immunosuppressant because of its ability to induce tolerance and drive 
T-cell anergy but compared to other immunosuppressants, rapamycin is not a calcinurin inhibitor, therefore 
it does not inhibit IL-2 transcription and secretion but instead the signalling effect IL-2 has on the cells. 
Rapamycin and its effect within transplant recipients has been extensively studied and well document and 
is regarded by many physicians as a favourable immunosuppressive medication, in combination with other 
drugs. 
Tol-DC have been used to show prolonged graft survival in C3H/HeJ mice receiving a heart allograft (180). 
Dendritic cells were isolated from mouse bone marrow and treated with 10ng/ml of rapamycin, inducing 
their differentiation into tol-DC. Phenotypic analysis of rapamycin treated DC (Rapa-DC) showed 
resistance to maturation with lipopolysaccharide (LPS). Rapa-DC also demonstrated decreased co-
stimulatory marker expression (CD80 and CD86) and MHC class II molecule as well as the ability to 
inhibit IL-2 and IFN-γ secretion from CD4+ and CD8+ T-cell respectively, when co-cultured at a ratio of 
1:10 (Rapa-DC:T-cells). Taner et al., showed that pulsing the Rapa-DC with allo-antigens prior to 
intravenous transfer into C3H heart graft recipients 7 days before receiving the transplant, graft survival 
could be prolonged significantly. Additionally, repetitive infusion with allo-antigen pulsed Rapa-DCs lead 
to indefinite graft survival (>100 days) in 40% of graft recipients. 
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Nanoparticle Therapy 
Nanoparticle use within medicine has become a rapidly increasing research area which explores 
applications including imaging (181, 182), vaccination (183, 184), biomolecule detection (185) and drug 
delivery (186, 187). The ability to construct nanoparticles using different materials and fabrication 
techniques, permitting changes in pore size, shape, coating and overall dimensions, allows these particles 
to develop diverse functions, this allows them to be considered for use in a variety of fields. 
The use of silicon for the manufacture of porous silicon nanoparticles (pSiNP) is a favourable element as 
its effect on cells has been well documented. As silicon is a trace element within humans and its degradation 
product is silicic acid, it poses no harmful effects in vitro or in vivo (188). The potential use of porous 
silicon nanoparticles for in vivo use was first published in 2009 by Park et al. The study showed 
biodegradability, low in vivo toxicity and homing of pSiNP when administered intravenously. It was shown 
that the particles accumulated within mononuclear phagocyte system (MPS) related organs, degrade within 
a few days and non-toxic by-products were removed via renal clearance, concluding that these particles 
have great potential for use in drug loading and delivery in vivo. 
In terms of scientific progression, research into the drug loading of porous silicon nanoparticles is still in 
its infancy. The concept of loading a drug into a pSiNP is quite simple to grasp, unfortunately many 
potential problems can arise. Polarity of the drug is one of the major issues when it comes to loading. 
Identifying solutions which allow for the drug to be dissolved without affecting the structural integrity of 
the nanoparticle or altering its half-life and surface chemistry can be problematic. Once within the particles, 
selecting nanoparticles which show the desired characteristic (particle geometry and pore size) for optimal 
drug diffusion rate can be a laborious process. Manufacturing nanoparticles with surface antibodies for cell 
targeting can lead to issues with binding, degradation and specificity of targeting antibody, which need to 
be overcome. 
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In 2012, Gu et al., identified the use of a porous silicon nanoparticle functionalised with agonistic antibody 
FGK45, used to target the CD40 receptor on APC (189). The nanoparticles were able to enhance the 
immune system via activation of antigen presenting cells. Their study showed that pSiNP functionalised 
with FGK45 were more readily taken up by APC compared to the unfunctionalised NP. Exposing APC to 
FGK45-pSiNP lead to a significantly enhanced response in B-cell activation. Furthermore, it was shown 
that the FGK45-pSiNP had a substantially higher activation potency than free FGK45 which required 
concentrations of 30-40 fold higher to produce the same level of B-cell activation. This experiment 
highlighted the importance of multivalency which is a significant advantage and feature of functionalised 
nanoparticles. 
Secret et al., (190) explored the use of functionalised porous silicon NP coated with several different cancer 
cell targeting antibodies and loaded with camptothecin. The study showed that the pSiNP were efficiently 
taken in by neuroblastoma cancer cells which express the corresponding receptor and release of 
camptothecin was significant to induce cancer cell death. Furthermore, they showed that pSiNP which 
were not functionalised were not absorbed by the cancer cells. These experiments confirmed the 
importance and specificity functionalisation can have, especially when the nanoparticles are loaded with 
potentially toxic chemotherapeutics. 
The dichotomous function of DC and their remarkable plasticity makes them a prime target for use in non-
conventional immunosuppressive therapy. A majority of the therapy currently explored involves in vitro 
manipulation of DC and infusion prior to transplantation or chronic, systemic immunosuppression 
administration, which can have detrimental effects, directed towards the patients lymphocytes. Utilising 
nanoparticles which are loaded with immuno-modulators and manufactured to target DC could permit in 
vivo manipulation of DC, as the NP will be infused directly into the recipient, and prevent the necessity for 
systemic immunosuppression as they will have targeted release directly affecting the cells of interest. 
Finally, Maldonado et al., (187) studied the use of biodegradable poly(lactide-co-glycan) (PLGA) 
nanoparticles which were loaded with rapamycin and ovalbumin (OVA) peptide or protein. The study 
explored the potential to induce immunological tolerance in Swiss Jack Lambert (SJL) mice which received 
OVA specific CD4+ T-cells and immunised subcutaneously with OVA323-339 admixed with TLR7/8 agonist. 
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It was observed that NP loaded with rapamycin and the OVA peptide could completely abrogate the 
proliferation of OVA specific CD4+ T-cells as well as increase the number of FoxP3+ T-regulatory cells. 
The studies also showed that they were capable of inducing B-cell tolerance, for at least 200 days, in mice 
that received the same nanoparticles. Interestingly, in order to induce tolerance, the nanoparticles needed 
to be loaded with both rapamycin and OVA. Free rapamycin or nanoparticles loaded with rapamycin only 
were unable to significantly decrease T-cell proliferation. Unfortunately this study did not assess the effect 
the nanoparticles had on dendritic cells but more the ability of NP to induces antigen specific T-cell 
tolerance and the humoral immune response. Therefore, the fate of these nanoparticles in vivo is a major 
gap in the knowledge. The nanoparticles may be directly acting on circulating T-cells or, more likely, track 
to the spleen, where they are taken in by dendritic cells. The rapamycin payload would then be released 
and this would promote the differentiation of immature DC into tolerogenic DC. Then with subsequent 
challenges with OVA, the protein would be processed and presented by the APC to OVA specific T-cells, 
promoting both T-cell anergy and CD4+ Treg differentiation. 
Conclusion 
Exploring the work of targeted nanoparticles offers opportunity to develop a nanoparticle which has the 
ability to specifically target key immune cells to suppress the immune system. Loading a nanoparticle with 
rapamycin and peptides has the ability to induce the differentiation of immature dendritic cells into tol-DC 
and suppress antigen specific T-cells. Furthermore, as DC are an extremely rare cell population, exploring 
the functionalisation of nanoparticles with DC-SIGN, allowing them to specifically target DC may permit 
a localised release of their payload. This would provide an effective means for delivering 
immunosuppressive medications at concentrations significantly lower than currently implemented, 
preventing the need for chronic immunosuppression and hence lowering the detrimental side effects these 
medications have on patients. 
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Thesis Hypotheses 
This thesis aims to develop on work carried out by Maldonado et al. (187), exploring nanoparticle mediated 
manipulation of the immune system, with a specific focus on dendritic cell (DC) induction of tolerance. 
Utilising a dendritic cell targeting, porous silicon nanoparticle, loaded with immunosuppressant, rapamycin 
we hypothesize: 
1. DC will favour differentiation into a maturation resistant, tolerogenic state.
2. Furthermore, we expect these DC to elicit the differentiation of naive CD4+ T-cells into
suppressive, regulatory T-cells. 
This thesis explores four main aims: 
1. To develop DC targeting, porous silicon nanoparticles.
2. To show an enhanced targeting ability to DC compared to non-targeting nanoparticles.
3. To induce maturation resistant phenotype and function within DC preconditioned with rapamycin
loaded nanoparticles and 
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S.O. Stead et al. / Biomaterials 155 (2018) 92 102 93tumour growth [11]. These realisations have led to an emerging
research focus on the use of nanoparticles to target immune cells,
including DC, for tolerogenicity in autoimmunity and cancer
immunotherapy [12e16].
pSi based nanoparticles (pSiNP) are generated by anodisation or
metal assisted chemical etching of single crystal silicon. They are
particularly promising due to their biocompatibility and biode
gradability, in contrast to the more frequently studied mesoporous
silica [17,18]. The breakdown product of pSiNP is silicic acid, a
nontoxic by product, which is filtered by the kidneys [19].
Furthermore, pSiNP also offer a very large surface area to volume
ratio for drug loading. By altering the anodisation conditions, par
ticle or pore size and shape, the loading and release of drug cargos
can be optimised. Surface chemistry allows for straightforward
covalent attachment of targeting ligands to the nanoparticle exte
rior, offering control over pore degradation and hence drug release
kinetics [20e22].
Allogeneic graft tolerance without dependency on immuno
suppressive medication has been referred to as the ‘Holy Grail’ of
transplantation since the early 1950's [23]. The driving forces of
tolerance involve several complex mechanisms, which involve the
key player of immunomodulation, the professional antigen pre
senting cells (APC) [24e27]. DC are the most potent APC, interact
ing with CD4þ and CD8þ T cells by processing and presenting
foreign peptides on MHC Class II and Class I proteins, respectively
[28,29]. DC have specific pathogen receptors including a C type
lectin called Dendritic Cell Specific Intercellular adhesion mole
cule 3 Grabbing Non integrin (DC SIGN) which plays an important
role in peptide presentation and elicits T cell activation upon
complement signalling by co stimulatory interactions and cytokine
secretions. DC, depending on their co stimulatory molecule
expression and their cytokine secretion profile, have been shown to
possess dichotomous functions of immunostimulation and immu
nosuppression [30e32].
A common and well studied immunomodulatory medication is
the macrolide molecule rapamycin (Sirolimus). Rapamycin is a
macrocyclic lactone product of Streptomyces hygroscopicus that
disrupts the mammalian target of rapamycin (mTOR) pathway.
Rapamycin's disruption of the mTORC1 subunit inhibits raptor
phosphorylation and downstream transcription factor activation
[33]. Rapamycin's effect on DC decreases co stimulatory marker
expression [14,34e37], preventing complete activation of inter
acting T cells, promoting T cell anergy and T regulatory (Treg) cell
production.
In this work, we used a nanoparticle targeting DC via their
uniquely expressed DC SIGN receptor for ex vivo immunomodula
tory treatment. The expected key advantage of this approach is that
targeted drug release reduces the total quantity of drug required to
elicit a response whilst minimising harmful “off target” side effects.
Phenotype and function of the DC were assessed by identifying
expression levels of markers of DC maturation and the stimulatory
capacity of allogeneic T cells bymixed lymphocyte reactions. In this
study, we showed that displaying DC specific antibodies on the
surface of pSiNP, enhanced uptake by the APC. Furthermore, we
were able to induce maturation resistance in human monocyte
derived DC when cultured with rapamycin loaded, targeting pSiNP.
1. Materials and methods
1.1. Fabrication and functionalisation of pSiNP
Pþþ type silicon (Si) wafers <100> with a resistivity of
0.8e1.2 mU/cm were electrochemically etched in a 3:1 mixture of
48% hydrofluoric acid (HF) to ethanol (EtOH). Silicon wafers were
etched with a square wave format pattern, alternating between50 mA/cm2 for 7.3 s and 400 mA/cm2 for 0.3 s for 1 h. The etched
surface was electropolished in a 1:20 solution of HF to EtOH at
4 mA/cm2 for 250 s. The porous layer was fractured by ultra
sonication and filtered through a 0.22 mm nylon filter (Sartorius,
G4ttingen, Germany). The resulting pSiNP underwent a hydro
silylation reaction by resuspension in 0.1 M of protected semi
carbazide (tert butyl 2 [(allylamino)carbonyl] hydrazine
carboxylate) [38] in tetrahydrofuran (THF) for 3 h at 85 C under
N2 reflux (Fig. 7). pSiNPwere rinsed twice in THF, twice in EtOH and
stored at 4 C. Boc group removal from the protected semi
carbazide was performed by resuspending NP in a 2:3 solution of
dichloromethane (CH2Cl2) and trifluoroacetic acid (TFA). pSiNP
were agitated for 4 h at room temperature (RT) and washed once in
CH2Cl2 and twice in EtOH.1.2. Quantification of pSiNP concentration
A known volume of pSiNP in EtOH was placed in a 2 ml
microcentrifuge tube (Eppendorf, Hamburg, German) of known
mass. The tube was placed in a vacuum centrifuge to remove the
EtOH and was re weighed to determine the NP mass per volume.1.3. Drug loading
Rapamycin powder (LC Laboratories, Boston, USA) was dissolved
in 100% undenatured EtOH at 2 mg/ml. Deprotected pSiNP were
resuspended in rapamycin solution and agitated for 2 h at RT. The
pSiNP were centrifuged at 22,000  g for 10 min and washed twice
in PBS. Drug loaded pSiNP (RAPA pSiNP) were analysed with a
Hyperion 2000 microscope (Bruker, Massachusetts, USA) for
infrared (IR) spectral analysis and cross referenced against pure
rapamycin samples to confirm successful drug loading. Release
kinetics was performed by loading pSiNP with C40 (glycyl 6
hexanoic (5(6) carboxamidofluorescien)) rapamycin (Tenova
Pharmaceuticals, California, USA). pSiNP were resuspended in
phosphate buffered saline (PBS) (pH 7.4) and placed in a 37 C
incubator. Released rapamycin was measured in the supernatant at
various time points, using a FLUOstar Optima fluorescent plate
reader (BMG Labtech, Ortenberg, Germany) with excitation at
485 nm and emission of 520 nm.1.4. Antibody oxidation
Human DC SIGN antibody (BD Biosciences, California, USA.
Clone DCN46) and Mouse IgG2k isotype control (z 150,000 Da)
(eBioscience, California, USA) antibody (0.5 mg/ml) were oxidised
with a 0.1 M solution of sodium periodate (NaIO4) at a 3000:1 M
ratio (NaIO4:antibody) and incubated on an orbital shaker in the
dark for 30 min (RT, 60 rpm). Antibodies were purified through
10,000 Da molecular weight cut off (MWCO) purification columns
(Sartorius) and washed three times in PBS (pH 7.4) by centrifuga
tion at 12,000  g for 10 min.1.5. Antibody conjugation to pSiNP
Semicarbazide functionalised, RAPA pSiNP were resuspended
in oxidised antibody. The solution was agitated in the dark for
30 min at RT. pSiNP were washed twice in PBS (22,000  g for
2 min) and left pelleted for fluorophore conjugation or resus
pended inmedia for immediate experimentation. Antibody binding
was confirmed by measuring the UV absorbance at 280 nm
(Nanodrop 2000, Thermo Scientific, Massachusetts, USA).
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Fluorescein isothiocyanate powder (Sigma Aldrich. Missouri,
USA) or XenoLight CF680 succinimidyl ester (SE) dye (Perkin Elmer,
Massachusetts, USA) was dissolved in a 0.1 M solution of sodium
carbonate buffer (Na2CO3, pH 9) to a concentration of 4 mg/ml.
Stock dye (10 ml) was diluted 100 fold in PBS and added to each
pelleted nanoparticle sample. Samples were placed on an orbital
shaker in the dark for 1 h (RT, 60 rpm). pSiNP were washed several
times in PBS (22,000  g, 2 min) until the supernatant was col
ourless. After the final wash, the pSiNP were resuspended in Ros
well Park Memorial Institute (RPMI) medium (Invitrogen,
Massachusetts, USA) supplemented with 10% foetal calf serum
(FCS).
1.7. Monocyte derived dendritic cell culture
Peripheral blood mononuclear cells (PBMC) were isolated from
50 ml of buffy coat (ARCBS agreement 16 07SA 19) by underlying
the bloodwith Ficoll hypaque (Lymphoprep, Stemcell Technologies,
Vancouver, Canada). The blood was centrifuged at 600  g for
20 min at RT (no break) to separate the blood and the PBMC.
Monocytes were isolated from PBMC by negative selection using
EasySep™ Human Monocyte enrichment kit (Stemcell Technolo
gies. Vancouver, Canada) following the manufacturer's protocol.
Briefly, cells (5  107 cells/ml) were treated with antibody enrich
ment cocktail for 10 min at 4 C, followed by incubation with
magnetic beads for 5 min. Cells were placed in a magnet (Stemcell
Technologies) for 2.5 min, allowing the purified CD14þ monocytes
to be poured off. Monocytes were resuspended in RPMI medium
supplemented with 1% penicillin streptomycin, 1% glutamine, 10%
FCS, 400 U/ml interleukin 4 (IL 4) (eBioscience) and 800 U/ml
granulocyte macrophage colony stimulating factor (GM CSF)
(kindly donated by Schering Plough) to a concentration of
1 106 cells/ml. At day 2, cells were treatedwith soluble rapamycin
or RAPA pSiNP. At day 5, immature dendritic cells (iDC) were
matured with 500 ng/ml of lipopolysaccharide (LPS) (Sigma
Aldrich, Missouri, USA) for 48 h.
1.8. Transmission electron microscopy (TEM)
DC (1  106 cells) and pSiNP were processed for TEM as previ
ously published [39]. Briefly, cells were fixed in EM fixative and
osmium tetroxide, dehydrated via an increasing EtOH concentra
tion gradient and embedded in resin before transferring to a Beem
capsule (Ted Pella, California, USA) for later sectioning and imaging.
Samples were imaged using a Philips CM100 TEM (Amsterdam,
Netherlands).
1.9. Nanoparticle breakdown kinetics
One milligram of pSiNP was resuspended in 0.4 ml of PBS (pH
7.4) and briefly sonicated to disperse the pellet. Samples were
resuspended to a final concentration of 0.25 mg/ml pSiNP in PBS.
Aliquots of 10 ml were taken at various time points. Samples were
diluted 1:1000 in MilliQ water and analysed for elemental silicon
on an Agilent 8800 Triple Quadrupole inductively coupled plasma
mass spectrometer (ICP MS) (Agilent, California, USA).
1.10. pSiNP targeting to dendritic cells
Non drug loaded, anti DC SIGN or non targeting isotype con
trol antibody labelled pSiNP were resuspended in RPMI culture
medium (2 mg/ml). pSiNP were added to a 24 well plate (BD Bio
sciences) at 50 mg/ml containing 1  106 monocyte derived DC or200 ml of whole blood. Cells were harvested at 30 min, 2 h and 24 h
for uptake analysis. Whole blood samples were harvested and
stained with Lineage cocktail, MHC class II (HLA DR), CD11c and
BDCA 2 (CD303) antibodies (Table S1), for myeloid DC population
gating. Red blood cells were lysed and cells fixed in FACS lysing
solution (BD Biosciences) for 20 min at RT prior to analysis on
FACSCanto II flow cytometer (BD Biosciences) and FSC Express
(version 4) (DeNovo, California, USA).
1.11. Dendritic cell phenotyping
DC were harvested and resuspended in FACS wash buffer (PBS,
1% FCS, 20 mM sodium azide), and blocked in 10% heat inactivated
rabbit serum, for 20 min at RT. Cells were then aliquoted into 5 ml
FACS polypropylene tubes (BD Biosciences) containing antibodies:
CD11c, CD14, CD40, CD80, CD83, CD86, CD209, MHC class I (pan
HLA ABC) and MHC class II (HLA DR) (Table S2). Staining was per
formed at 4 C for 20 min. Cells were then analysed by flow
cytometry.
1.12. Mixed lymphocyte reaction
RAPA pSiNP preconditioned DC were harvested and washed in
RPMI,10% FCS. Cells were resuspended to 1 105 cells/ml in culture
medium and seeded in triplicate in a 96 well round bottom plate
(BD Biosciences) at a ratio of 1:10 DC:T cells. CD3þ T cells were
isolated from allogeneic PBMC via magnetic bead enrichment
(Stemcell Technologies) and CFDA SE (5 mM) (Thermo Scientific) or
Violet proliferation dye (5 mM) (Life Technologies) stained prior to
seeding. The plate was incubated (37 C, 5% CO2) for 4 days. Cells
were harvested and washed with FACS washing buffer and stained
at 4 C for 20 min with CD3 (OKT3; eBioscience) and CD4 (MT310;
Dako, California, USA) antibodies. Cells were fixed and analysed by
flow cytometry to identify proliferation levels.
2. Results
pSiNP were generated by applying high current density steps
periodically in between lower current density anodisation of silicon
wafers to separate layers of desired porosity, thin ‘sacrificial’ sec
tions of much higher porosity, followed by sonication and centri
fugation [7,40]. Transmission electron microscopy (TEM) was used
along with dynamic light scattering (DLS) to determine nano
particle morphology and size distribution. Fig. S1 (AeC) shows
three TEM micrographs of pSiNP (panel A top view, B and C size
views). The etching method produced plate shaped pSiNP with
pores running perpendicular through the plates' plane. DLS showed
the pSiNP had an average size of 160 nm (±4 nm). Fig. S1 D shows
the kinetics of nanoparticle degradation at physiological pH 7.4
obtained by quantifying elemental silicon with inductively coupled
plasma mass spectrometry (ICP MS). Particles exhibited a rapid
initial break down and within approximately 24 h, pSiNP were
completely degraded. These degradation kinetics were acceptable
for the in vitro testing as initial tracking experiments confirmed that
a majority of the pSiNP binding occurred within 24 h. The pSiNP
were functionalised with a protected semicarbazide linker via
hydrosilylation. Upon removal of the protective Boc group, the
particle surface was reacted with periodate oxidised monoclonal
antibodies, DC SIGN or Isotype control IgG after loading with
immunosuppressant, rapamycin (Fig. 1).
DC SIGN modified pSiNP were rapidly taken up by human
monocyte derived DC at 37 C, indicating that pSiNP were phago
cytosed in a time and dose dependent manner. Fig. 2A shows a
TEM of untreated DC. DC cultured with anti DC SIGN antibody
conjugated to pSiNP (DC SIGN pSiNP) (100 mg/ml) for 30 min
Fig. 1. Reaction for functionalisation, drug loading and antibody immobilisation on pSiNP surface. Silicon hydride terminated pSiNP undergo hydrosilylation with protected
semicarbazide in a solution of tetrahydrofuran (THF). pSiNP are deprotected in trifluoroacetic anhydride (TFAA) and dichloromethane (CH2Cl2) prior to drug loading and conjugation
of periodate-oxidised antibodies.
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and lysosomal internalisation of the pSiNP increased at 2 h and
showed further increase at 24 h (Fig. 2C and D respectively). Using
FITC labelled pSiNP, DC cultured with non targeting, isotype con
trol antibody displaying pSiNP (isotype pSiNP) (Fig. 2F) showed
lower FITC staining after 2 h incubation when compared to cells
incubated with anti DC SIGN pSiNP (Fig. 2G). Fig. 2H shows that
20 mg/ml and 50 mg/ml of DC SIGN pSiNP were phagocytosed more
rapidly compared to the isotype pSiNP control at all time points.
Incubating DC with pSiNP at a concentration of 20 mg/ml for 30 min
showed a 73% positivity for the targeting DC SIGN pSiNP compared
to 17% for the non targeting isotype pSiNP. Increasing the nano
particle concentration to 50 mg/ml showed an increased uptake of
DC SIGN pSiNP to 91% compared to 46% of the isotype pSiNP
(Fig. 2H). At 24 h, >94% of the human monocyte derived DC pop
ulation was positive for either isotype or DC SIGN pSiNP at both 20
and 50 mg/ml. However, as indicated by the mean fluorescence
intensity (MFI), DC phagocytosed approximately 2 fold more pSiNP
when they displayed the DC SIGN antibody. Isotype pSiNP were
non specifically taken up by the DC and were seen to not bind the
DC SIGN receptor, indicated by the high level of DC SIGN surface
staining with the fluorescently labelled antibody CD209. In
contrast, DC cultured with DC SIGN pSiNP had decreased receptor
tagging due to the competitive binding of the DC SIGN pSiNP to the
same receptor epitope, which did not permit the binding of the
fluorescent antibody (Fig. S2). The decrease in CD209 staining on
the DC cultured with DC SIGN pSiNP confirmed that oxidation of
the conjugated antibodies did not impair their function.
Myeloid DC were assessed for their nanoparticle uptake effi
ciency in a whole blood assay. FITC expression (proportional to
pSiNP uptake) was measured within the lineage negative, MHC
class II positive, CD11c positive (LinHLA DRþCD11cþ) DC popula
tion (Fig. 3A). After 24 h incubation, approximately 42% of the
myeloid DC population was positive for DC SIGN pSiNP compared
to only 11% of the DC culturedwith isotype pSiNP (Fig. 3B). Fig. 3C is
a graphical representation of the MFI of DC cultured with fluo
rescently labelled pSiNP displaying monoclonal antibodies. A sta
tistically significant difference between MFI (p < 0.001) wasobserved between DC cultured with isotype (1751 ± 83) and DC
SIGN (3065 ± 109) pSiNP after 24 h confirming that DC SIGN
pSiNP were taken up approximately 2 fold more effectively than
the control isotype pSiNP.
pSiNP were incubated in a 2 mg/ml solution of rapamycin for
2 h at RT followed by washing in PBS. As the functional groups of
rapamycin possess infrared spectral features distinct from pSi,
infrared spectroscopy was employed to confirm successful rapa
mycin loading within the pSiNP. RAPA pSiNP's IR spectrum showed
bands corresponding to the macrocyclic groups at 1452, 2875, 2911
and 2964 cm1, the triene portion of the rapamycin molecule at
1643 and 3026 cm1 and a peak at 1720 cm1, corresponding to the
carbonyl groups present (Fig. 4Aa). The peaks were also seen in IR
spectrum from pure rapamycin crystals (Fig. 4Ab). pSiNP not loaded
with drug showed no peaks at these positions (Fig. 4Ac). Nano
particle release kinetics were determined by quantification of
fluorescent rapamycin (lemission 520 nm) detected in the super
natant of the release buffer (PBS, pH 7.4) (Fig. 4B). The particles
followed a sigmoidal regression (r2 0.98), with 50% of the drug
being released within the first 4 h. From the maximumvalue, it was
calculated that RAPA pSiNP released a total of 5% w/w (rapamycin/
pSiNP). Therefore, subsequent experiments utilised 183 ng of RAPA
pSiNP per ml to deliver an equivalent of 10 nM rapamycin. This
concentration was also used in the free rapamycin control group.
DC treated with free rapamycin showed maturation resistant
characteristics after stimulationwith LPS with approximately a 1.5
fold lower expression of co stimulatory marker CD40 and MHC
class II, a 2 fold reduction in CD80, MHC class I and maturation
marker CD83 and an approximate 4 fold reduction in CD86
compared to mature DC (Fig. 5B). DC preconditioned with DC SIGN
RAPA pSiNP showed maturation resistance upon LPS stimulation,
with comparable surface marker expression levels to the free
rapamycin control. Increases in the mean surface expression of co
stimulatorymarkers CD40, CD83, MHC class I andMHC class II were
seen for DC treated with rapamycin loaded isotype pSiNP
compared to DC SIGN RAPA pSiNP (Fig. 5). Culturing DCwith either
isotype or DC SIGN pSiNP at low concentrations in the absence of
rapamycin resulted in insignificant receptor expression change
Fig. 2. (A D) TEM micrographs of mature DC (mDC). (A) Untreated mDC. (B, C, D) mDC treated with 100 mg/ml of DC-SIGN pSiNP and cultured for 30 min, 2 h and 24 h. Arrows
indicate surface binding and internalisation of pSiNP. Scale bar represents 2 mm. (E G) Fluorescence microscopy of mDC. (E) Untreated mDC. mDC cultured with 100 mg/ml of FITC-
labelled isotype pSiNP (F) or DC-SIGN pSiNP (G) taken at 24 h. Scale bar represents 40 mm at 40 magnification. (H) Flow cytometry histograms representing nanoparticle uptake
was dependent on DC-SIGN display. Monocyte-derived DC treated with 20 mg/ml or 50 mg/ml of isotype pSiNP (Black line) or DC-SIGN pSiNP (Blue shaded) at 30 min, 2 h and 24 h
(n 9, data is representative of one blood donor). Dashed line represents untreated DC control. Histograms show mean fluorescence intensity (MFI) and % positivity in parentheses.
(For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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Fig. 3. DC-SIGN pSiNP were favourably phagocytosed compared to isotype pSiNP (A) Gating strategy for myeloid DC population in whole blood samples. Peripheral blood from
healthy donors was incubated with pSiNP. Myeloid DC population was gated as lineage (CD2 , CD3 , CD14 , CD16 , CD19 , CD56 and CD235a ), HLA-DRþ (oval) and CD11cþ
(rectangle). The level of FITC expression within the population was used to determine pSiNP uptake by myeloid DC. (B) pSiNP target myeloid DC population in whole blood. Flow
cytometric analysis confirmed the uptake of isotype pSiNP (Black line) and DC-SIGN pSiNP (Blue shaded) within myeloid DC at 2 h and 24 h, compared to untreated DC (Dashed
line). The nanoparticle concentration used was 50 mg/ml. (C) MFI was approximately 2-fold higher in myeloid DC incubated with DC-SIGN pSiNP (Blue column) compared to isotype
pSiNP (white column) at 24 h. This indicated a greater uptake of DC-SIGN functionalised pSiNP compared to the non-targeting control isotype pSiNP in a whole blood setting. Data
are representative of one blood donor out of three independent experiments (n 3), statistical significance identified by unpaired t-test, ****p < 0.0001. (For interpretation of the
references to colour in this figure legend, the reader is referred to the web version of this article.)
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Fig. 4. (A) FTIR spectra of (a) rapamycin-loaded pSiNP (b) pure rapamycin crystals and
(c) unloaded pSiNP. Characteristic peaks of pure rapamycin at 1452, 1643, 1720, 2875,
2931, 2965 and 3026 cm 1 were present within the RAPA-pSiNP and absent in the
unloaded samples, confirming successful drug loading. (B) Release kinetics of fluo-
rescent rapamycin from pSiNP in PBS (pH 7.4) over 36 h. 50% of rapamycin is released
within the first 4 h. Data represented as mean ± SEM, n 3.
S.O. Stead et al. / Biomaterials 155 (2018) 92 10298compared to untreated immature DC, at low concentrations. A
significant increase of 1.6 fold was seen for maturation marker
CD83, only when DC were exposed to pSiNP concentrations 500
fold higher (i.e. 100 mg/ml) than what we used in this study when
loaded with rapamycin (z200 ng/ml) (Fig. 6).
Immature DC were an important negative control in this study,
due to their poor ability to stimulate allogeneic T cell proliferation,
therefore serving as an optimal comparison to show maturation
resistance in the matured, rapamycin treated DC. The immature DC
were poor allogeneic T cell stimulators, producing an average T cell
proliferative response of 13%. In contrast, mature DC were more
potent T cell stimulators, up regulating 26% of allogeneic T cells.
Matured, rapamycin preconditioned DC either receiving free rapa
mycin or isotype and DC SIGN RAPA pSiNP, maintained poor T cell
stimulatory abilities in vitro (Fig. 6). The treatment of DC with these
rapamycin formulations, even for matured cells, resulted in an
average proliferation of 14%, a reduction of approximately 50% in
proliferating allogeneic T cells, compared to mature DC not treated
with rapamycin.3. Discussion
In this study, we used biodegradable pSiNP, which we have
recently characterised [41], of 160 nm size which were function
alised by a semicarbazide linker (Fig. 7). These pSiNP enabled the
direct conjugation of periodate oxidised cell targeting antibodies to
their surface. Exploiting this principle, we have recently described
the vectorisation of a hydrophobic anticancer drug using antibody
functionalised pSiNP to cancer cells [7,42,43]. We explored camp
tothecin loaded, p75NTR antibody functionalised pSiNP fortargeting to neuroblastoma cells. When compared to their non
targeting control nanoparticles, anti p75NTR pSiNP decreased
neuroblastoma cell viability by approximately 80%. The porous
nature of pSiNP creates a reservoir for the loading of small molecule
drugs. The introduction of foreign materials into a homeostatic
environment can induce an inflammatory response, leading to the
maturation of immature DC, potentially diminishing the immuno
suppressive effectiveness of the drug. pSiNP were shown not to
stimulate immature DC at low concentrations (Fig. 5), preserving
the immunosuppressive potency of rapamycin.
Immunomodulators such as azathioprine, prednisolone, and
mycophenolic acid have all been shown to play a role in the sup
pression of the immune system [44e46]. With long term use, most
of these drugs result in severe cytotoxic side effects and increased
susceptibility of developing opportunistic infections and cancer
[47]. The macrolide compound rapamycin disrupts the IL 2
pathway by the formation of a rapamycin FKBP12 complex,
which acts as an allosteric inhibitor of mammalian target of rapa
mycin (mTOR), preventing downstream signalling [48,49]. The
extensive research into the maturation resistant effects of rapa
mycin on DC and its clinical relevance made it the drug of interest
for immunomodulation. Rapamycin was loaded into the pSiNP by
passive diffusionwith the antibody being directly conjugated to the
surface by a chemical linker. When placed in culture, rapamycin
was seen to diffuse from the particles with a standard sigmoidal
drug release kinetic profile; with 50% of the drug released within
the first 4 h. This was determined by measuring the relative fluo
rescence intensity of the fluorescent rapamycin analogy present
within the culture medium. We have shown consistent results in
the production of a maturation resistant DC when treated with
RAPA pSiNP, similar to the free rapamycin control and other studies
[34,50,51]. Myeloid DC representing less than 1% of total peripheral
blood leukocytes [52] play a major role in the stimulation of T cells
via complement signalling and IL 12 secretion [53]. IL 12 contrib
utes to the differentiation of naïve CD4þ T cells into T helper 1
(Th1) cells, and promoting interferon gamma (IFN g), tumour ne
crosis factor alpha (TNF a) secretion and natural killer (NK) T cell
production [54e56]. Recruitment of macrophages to a transplanted
site via mature myeloid DC stimulation contributes to the overall
foreign organ destruction, inevitably leading to graft rejection [57].
Inducing maturation resistance within the myeloid DC population
has the potential to prevent foreign organ rejection; and this could
be achieved by ex vivo targeting and preconditioning of myeloid DC
with rapamycin. Therefore, promoting T cell anergy and CD4þ Treg
cell production. Treg cells can lead to the secretion of IL 10
contributing to the suppression of DC, as shown by Fassbender
et al. [58]. Furthermore, due to rapamycin's unique ability to pro
mote Treg cells, this could induce a tolerogenic state within the
immune system promoting indefinite allo graft survival devoid of
immunosuppression.We surmised that if we found away to deliver
rapamycin via a nanocarrier, normal cell processes would be un
affected, preventing systemic suppression of the immune system;
and that implementing a nanoparticle based delivery strategy for
rapamycin, we could provide a means of enhanced and localised
delivery. We were encouraged by the results of Das et al. and
Jhunjhunwala et al. [59,60]. who showed that utilising PLGA
nanoparticles for the intracellular delivery of rapamycin to DC had a
more potent effect than conventional systemic administration.
Since DC SIGN is highly expressed on immature myeloid DC and on
a small population of BDCA2þ precursor placmacytoid DC in the
blood [61], it is a prime candidate for specific cell targeting. Here,
we achieved this by covalent conjugation of DC SIGN antibody to
the surface of pSiNP. This approach allowed us to investigate
actively targeted rapamycin delivery to DC to induce a maturation
resistant phenotype. With the identification of unique cell markers,
Fig. 5. (A) Flow cytometric histograms of DC preconditioned with rapamycin. Monocyte-derived immature DC were treated with 10 nM of rapamycin at day 2, added directly to the
supernatant (free rapamycin) or delivered via pSiNP. Maturation resistant phenotype was seen in DC preconditioned with free rapamycin and RAPA-pSiNP, panel is representative of
one donor. (B) Graphs represent the MFI fold change compared to immature DC of co-stimulatory markers CD40, CD80 and CD86 along with DC maturation marker CD83 and major
histocompatibility complexes I and II; Data represented as mean ± SEM n 6, statistical significance identified by One-way ANOVA *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
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nanoparticles could be adapted to carry a range of drugs to target a
wide range of cells both ex vivo and in vivo.
Due to the phagocytic nature of DC, non specific uptake was
observed with isotype pSiNP when cultured for 24 h. Therefore,
isotype RAPA pSiNP induced similar maturation resistant pheno
types of human monocyte derived DC compared to DC SIGN pSiNP.However, when placed in a more complex ex vivo setting such as
whole blood, the benefits of displaying DC SIGN were evident:
uptake of DC SIGN pSiNP was up to 4 fold greater compared to
isotype pSiNP over the same time frame of 24 h. When nano
particles are placed in a whole blood setting, corona formation
occurs from plasma protein binding the surface [63]. These coronas
have been well studied, and have shown to impede uptake
Fig. 7. Gating strategy for T-cell mixed lymphocyte reaction. T-cells were stained with
violet proliferation dye. Violet stain dilution was used to determine total proliferation
levels of purified CD3þ T-cells when co-cultured with preconditioned matured DC at a
10:1 ratio. DC preconditioned with rapamycin either via pSiNP or addition of free drug
(10 nM) directly in the supernatant were both poor stimulators of T-cells proliferation
when compared to untreated mDC. Statistical significance indicated by an *, compared
to mature DC. n 6. ***p < 0.001, ****p < 0.0001.
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kinetics [64e67]. Therefore, within a ex vivo setting with large
volumes of whole blood, it may be theorised that DC SIGN pSiNP
will require longer incubation times or higher dosage to adequately
target low abundance cell populations, such as the DC.
Due to the non specific uptake of the isotype RAPA pSiNP over
the 24 h co culture, enough rapamycinwas released which resulted
in DC with poor allogeneic stimulatory abilities (Fig. 7B). Within a
single cell culture setting this is expected, due to the inability to
remove the unbound nanoparticles after a short incubation time.
During this time, DC SIGN RAPA pSiNP bound significantly more
than the isotype pSiNP based on the tracking data. As the particles
were internalised in a time dependant manner, in both a single cell
culture and within whole blood, it was hypothesised that in an
ex vivo setting, less rapamycin would diffuse out of the DC SIGN
RAPA pSiNP before reaching its targeted cell. Whereas utilising an
isotype pSiNP would result in a lower delivery of rapamycin to the
DC, as the time to target the cells would be longer. This would resultFig. 6. Immunogenicity of immature human monocyte-derived dendritic cells co-
cultured with isotype or DC-SIGN pSiNP over 48 h pSiNP treated DC maintained
immature phenotype with concentrations <100 mg/ml. At concentration 100 mg/ml of
either isotype or DC-SIGN pSiNP a 1.7-fold increase in maturation marker CD83 was
seen compared to immature DC. Data represented as mean ± SEM n 5, statistical
significance identified by One-way ANOVA, *p < 0.05, ****p < 0.001.
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the circulation. The end effect would be that a considerably lower
mass of DC SIGN RAPA pSiNP would be required compared to a
non targeted formulation.
A limitation of our study was the extended culture period of
monocyte derived DC with the drug loaded nanoparticles. The
non specific uptake and diffusion kinetics of the particles inevi
tably lead to the lack of dichotomy between DC phenotype and
function when treated with targeting or non targeting pSiNP
(Fig. 5B). However, the initial in vitro tracking experiments showed
that within the first 2 h, functionalisation of pSiNP with targeting
monoclonal antibody (DC SIGN) was highly beneficial for rapid
uptake by DC (Fig. 2H). Future experiments will focus on using flow
cytometric sorting to remove unbound pSiNP after short incubation
times as well as an in vivo tracking model to identify the bio
distribution of the DC targeting pSiNP compared to non targeting
pSiNP.
4. Conclusion
Herewe report an immunomodulatory approach utilising RAPA
pSiNP targeting DC via their uniquely expressed receptor, human
DC SIGN. Human monocyte derived DC cultured with DC SIGN
pSiNP showed approximately a 3 fold increased uptake efficiency
compared to isotype pSiNP within the first 30 min and at 24 h
approximately a 2 fold greater uptake amount of DC SIGN pSiNP
indicated by the MFI. Furthermore, within whole blood, DC SIGN
antibody functionalisation permitted a 4 fold greater uptake by
myeloid DC, one of the least abundant cell populations in the hu
man body. Preconditioning DC with RAPA pSiNP resulted in
phenotypically immature DC upon maturation, which displayed
poor allogeneic T cell stimulatory capabilities compared to the
mature DC. DC SIGN pSiNP therefore provide an effectivemeans for
delivering immunosuppressive medications directly to a DC pop
ulation ex vivowith an increased capacity and in a reduced amount
of time compared to non targeting pSiNP.
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Murine and Non-Human Primate Dendritic Cell Targeting 
Nanoparticles for In Vivo Generation of Regulatory T-cells

Dendritic cells (DC) within the immune system are
responsible for processing and presenting foreign peptides,
inducing an immune response toward an allogeneic transplant.
DC are the most potent of the antigen presenting cells (APC),
capable both of immunostimulation and immunosuppression
and drive antigen specific tolerance by promoting regulatory
T cell (Treg) production.3,4 One promising approach is the
induction of tolerance to allogeneic grafts via targeting DC
with drug loaded nanoparticles designed to dampen immune
responsiveness and generate “tolerogenic DC” (tol DC). The
use of tol DC in transplantation, as an immune therapy, has
developed significant traction in recent years, with several
clinical trials investigating the benefits of in vivo DC therapy.5,6
Rapamycin is a commonly used immunosuppressive
medication that promotes formation of tol DC.7 Precondition
ing DC with rapamycin induces a maturation resistant
phenotype, characterized by decreased co stimulatory and
maturation markers expression,8−10 which can induce T cell
anergy and promote Treg generation.11 DC also express
specific surface molecules including the c type lectin, dendritic
cell specific intercellular adhesion molecule 3 grabbing non
integrin (DC SIGN; CD209). Coupling DC SIGN mono
clonal antibodies to porous silicon drug loaded nanoparticles
creates a method to specifically target DC in vivo. Utilizing
targeting, drug loaded nanocarriers that deliver therapeutics
specifically to these key immune cells, has the potential to
Figure 1. CD11c pSiNP track predominately to the kidneys, followed by the liver, spleen, lungs, and heart. (A) Individual organs taken from
the mice at 24 h post injection (i.v.) with fluorescent pSiNP. Heat map (red to yellow) indicates presence of pSiNP. (B) Quantification of
total fluorescence as radiant efficiencies of each of the organs at 24 h. Mice injected with CD11c pSiNP had approximately 10 fold higher
levels in the spleen compared to isotype pSiNP. CD11c pSiNP tracked significantly more to the kidneys and lungs of the mice compared to
isotype pSiNP. Insignificant presence of pSiNP was seen within the lungs and heart. (Data are represented as mean ± SD, n = 3 per group,
significance determined by one way ANOVA, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001).
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reduce off targeted drug effects. Here, we studied the uptake of
DC targeting porous silicon nanoparticles (pSiNP), function
alized with antibodies to murine CD11c and human/non
human primate (NHP) DC SIGN in vivo. Rapamycin loaded
pSiNP were also assessed in their ability to generate Treg in
vivo in an ovalbumin (OVA) sensitized murine model. We
utilized both a murine and a NHP model to investigate the
hypothesis that displaying DC targeting antibodies on pSiNP
would permit a higher level of cell targeting in vivo compared
to their non targeting counterparts.
RESULTS
Murine DC Targeting with CD11c-pSiNP. Porous silicon
nanoparticles (pSiNP), <200 nm in size, manufactured by
alternating high and low current density anodization of silicon
wafers, were functionalized with a protected semicarbazide
linker via hydrosilylation.12 Boc group removal from the
pSiNP surface permitted reaction with periodate oxidized
mAb and fluorescent tag, CF680, both of which covalently
link directly to the NP. Murine CD11c integrin has been used
extensively to categorize myeloid lineage negative, MHC class
II+CD4+CD8α − and MHC class II+CD4−CD8α + DC
subsets.13 Due to the highly unique expression of CD11c on
myeloid DC subsets, it served as a prime target for pSiNP
within a murine model. Isotype and CD11c pSiNP were
administered intravenous (i.v.) to mice. Whole body images
showed nanoparticle accumulation within the kidney of mice
injected with either isotype or CD11c pSINP, most prominent
within the first hour. The fluorescence was seen to dissipate in
a time dependent manner (Figure S1A). However, quantifica
tion of organ fluorescence (Figure 1A,B) as radiant efficiencies
(RE), the fluorescence emission radiance per incident
excitation irradiance, showed both isotype and CD11c pSiNP
accumulation was time dependent. Isotype pSiNP mice
showed a maximum pSiNP accumulation in the liver (1.2 ×
108 RE), spleen (2.2 × 107 RE), and kidneys (4.2 × 108 RE) at
6 h and lungs (2.1 × 107 RE) at 12 h (Figure S1) with no
significant heart uptake. Kidney fluorescence was 14 fold
higher than the saline control at 6 and 24 h (Figure S1 and
Figure 1). CD11c pSiNP mice had significantly higher pSiNP
accumulation in the liver, lungs, heart, spleen and kidneys
compared to both the saline and isotype pSiNP control mice.
Maximum fluorescence was seen in the liver (2.3 × 108 RE)
and spleen (1.2 × 108 RE) at 24 h (Figure 1), and the lungs
(4.3 × 107 RE), kidneys (1.2 × 109 RE), and heart (1.6 × 107
RE) at 12 h (Figure S1). CD11c pSiNP accumulated 10 fold
Figure 2. CD11c pSiNP track to murine splenic myeloid CD4+ and CD8α+DC in vivo. (A) Gating strategy of lineage negative MHC II+CD4+
or CD8α+DC, MHC II+CD11b−CD11c+DC, and MHC II+CD11b+CD11c− macrophages. (B) Quantification of the mean fluorescence
intensity (MFI), representative of pSiNP accumulation, within splenic and blood DC and macrophage populations. CD4+ and CD8α+ DC
showed approximately 9 fold and 31 fold higher levels of CD11c pSiNP, respectively, in the spleen at 24 h. Data are presented as delta (Δ)
MFI ± SD, normalized to the baseline fluorescence levels in saline injected control animals (n = 3 per group, statistical significance
determined by two tailed t test, * p < 0.05, **** p < 0.0001).
ACS Nano Article
DOI: 10.1021/acsnano.8b01625
ACS Nano 2018, 12, 6637−6647
6639
higher than isotype pSiNP in the spleen at 6 and 24 h (Figure
1). CD11c pSiNP mice splenic fluorescence decreased by
approximately 60% from 6 to 12 h, accompanied by increased
presence in the heart and kidneys at 12 h (Figure S1).
The flow cytometric gating strategy utilized the lineage
negative population to remove T cells, B cells, and NK cells
while focusing on the MHC II+ population (Figure 2A, middle
left panel). This population contains both myeloid and
conventional DC and is therefore further divided into both
CD4+ and CD8α+ subsets (Figure 2A, bottom left panel).
These populations within the spleen identified accumulation of
pSiNP in mice injected with either CD11c or isotype pSiNP.
Both CD4+ and CD8α+ conventional DC subsets were positive
for CD11c pSiNP at 24 h. CD4+ and CD8α+ DC had
approximately a 9 fold and 31 fold higher uptake of CD11c
pSiNP, respectively, compared to isotype pSiNP (Figure 2).
The MHC II populat ion was also divided into
CD11b−CD11c+ and CD11b+CD11c− (Figure 2A, right
lower panel) to highlight the total nanoparticle accumulation
within the CD11c+ DC and CD11b+ macrophage populations.
MHC II+CD11b−CD11c+ splenic DC showed positivity for
CD11c pSiNP and no detectable levels of isotype pSiNP
(Figure 2). Splenic MHC II+CD11b+CD11c− macrophages14
accumulated CD11c pSiNP 4 fold higher than isotype pSiNP
after 24 h (Figure 2). CD11c pSiNP were preferentially taken
up by the MHC II+ CD11b−CD11c+ population within the
peripheral blood, at 12 and 24 h, with no detectable uptake of
isotype pSiNP (Figure S2 and Figure 2, respectively). Blood
macrophages were positive for isotype pSiNP at 1, 12, and 24
h, however, blood DC and macrophage populations indicated
no significance uptake between isotype or CD11c pSiNP
(Figure S2 and Figure 2). Injecting mice with dye conjugated
directly to the antibody in the absence of nanoparticles allowed
us to identify differences in biodistribition compared to
functionalized pSiNP (Figure S3). Quantification of organ
fluorescence in mice injected with isotype or CD11c antibodies
only was markedly different to antibodies conjugation to
fluorescent pSiNP. Significant differences between isotype and
CD11c Ab mice were only observed in the left kidney and the
heart, but not the liver or the spleen (Figure S3B). Neither of
the splenic and blood DC populations displayed any significant
difference between isotype and CD11c antibody injected
animals (Figure S3C).
Histological sections displayed brown aggregates in the liver
and spleen of CD11c pSiNP and isotype pSiNP mice,
respectively (Figure S4). No large aggregates were observed
in the heart, lungs, or kidneys. The organs appeared healthy
compared to the control animals, with no detectable
inflammation. CD11c (PE) and MHC II (FITC) splenic
staining confirmed co localization of CD11c and pSiNP
supporting observations from flow cytometry (Figure S4).
Murine Regulatory T-Cell Generation with pSiNP. The
pSiNP pores (21 ± 11 nm diameter) allow them to be loaded
with drugs and peptides.12 We recently showed consistent
rapamycin loading (5% w/w) via passive diffusion into the
pSiNP pores. This loading regime equated to 1 mg/kg of
rapamycin per 20 mg/kg of pSiNP.15 The cytometric gating
highlights the total lymphocyte population. Focusing on this,
we isolated CD4 and FoxP3 expressing cells, then further
expanding this population to identify the proportion expressing
high levels of CD25, obtaining CD4+ CD25+ FoxP3+ Treg
(Figure 3A, left to right). Staining of the splenic Treg, 40 days
following final intravenous injection, was approximately 5 fold
higher (p < 0.01) in mice receiving CD11c pSiNP loaded with
OVA323−339 and rapamycin compared to the saline control,
positive control, fRapamycin, (±OVA323−339), and isotype
pSiNP (OVA + rapamycin) mice (Figure 3). Mice receiving
CD11c pSiNP loaded with only rapamycin displayed an
increase of approximately 2.5 fold in total splenic Treg
concentrations, although not significant (p = 0.1).
Nonhuman Primate DC Targeting DC-SIGN-pSiNP.
DC specific receptor DC SIGN is expressed on non human
primate and human DC.16 Isotype and DC SIGN pSiNP
accumulated predominantly in the kidneys and liver, with DC
SIGN pSiNP also showing up in the lungs of the marmosets
(Figure 4). Isotype pSiNP marmoset organs displayed high
fluorescence in the kidneys (3.0 × 108 RE), liver (1.8 × 108
RE), and spleen (1.4 × 108 RE), with small amounts of
fluorescence detected in the lungs (2.5 × 107 RE) and heart
(2.5 × 107 RE). DC SIGN pSiNP tracked mostly to the
kidneys (5.0 × 108 RE), followed by the liver (6.5 × 107 RE),
Figure 3. Injections of rapamycin and peptide loaded CD11c
pSiNP promote Treg production in vivo up to 40 days post
in jec t ion . (A) Gat ing s t rategy of mur ine sp lenic
CD4+FoxP3+CD25+ Treg. (B) Treg were counted using flow
cytometer counting beads to determine the concentration of Treg
in OVA sensitized mice spleen. Mice which received CD11c pSiNP
(i.v.) loaded with OVA323−339 peptide and rapamycin showed an
approximate 5 fold increase in the number of splenic Treg
compared to the untreated control mice and mice receiving free
rapamycin and/or peptide (fRapamycin ± fOVA) with or without
pSiNP delivery. (Data are represented as mean ± SEM, n = 5 per
group with the exception of CD11c pSiNP (OVA + rapamycin) n =
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lungs (5.0 × 107 RE), heart (3.9 × 107), and spleen (1.0 × 107
RE) within 24 h.
The lineage negative, MHC II+CD11c+ splenic myeloid DC
population indicated a 3.5 fold uptake increase of the isotype
pSiNP compared to the DC SIGN pSiNP. Blood myeloid DC
had detectable levels of DC SIGN pSiNP in one of the three
marmosets, whereas isotype pSiNP was not seen in blood
myeloid DC (Figure 5). Splenic CD14+ monocytes showed an
uptake of DC SIGN pSiNP with no detectable levels of
isotype pSiNP. Blood monocytes accumulated isotype pSiNP
approximately 2 fold more than DC SIGN pSiNP, although no
significant difference was observed (Figure 5). Splenic CD20+
B cells showed a 7 fold greater positivity for isotype pSiNP
compared to DC SIGN pSiNP. No off targeting uptake of
pSiNP was observed by CD3+ T cells and CD56+ natural killer
cells.
Urine analyzed by inductive coupled plasma mass spectrom
etry (ICP MS) quantified boron and silicon deposits within
Figure 4. CD SIGN pSiNP track predominately to the kidneys, followed by the liver, spleen, lungs, and heart. (A) Topographical distribution
of fluorescent pSiNP in marmosets at 24 h indicated by blue color. Isotype pSiNP (top) accumulated around kidneys and liver; DC SIGN
pSiNP (bottom), present in the kidneys and lungs of marmosets. (B) Individual organs taken from the marmosets at 24 h post injection
(i.v.) with fluorescent pSiNP. Heat map (red to yellow) indicates presence of pSiNP. (C) Quantification of total fluorescence as radiant
efficiencies of each of the organs at 24 h. Marmosets injected with CD11c pSiNP showed a higher level in the kidneys compared to
marmosets which received isotype pSiNP. DC SIGN pSiNP tracked highly to the lungs of the animals. DC SIGN pSiNP has significantly
greater deposition within the kidneys compared to isotype pSiNP, which were seen to accumulate significantly more within the livers of the
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the urine. Isotype pSiNP marmosets displayed a 10 fold (6
ppm) and 7 fold (103 ppm) higher concentration of boron and
silicon in the urine, respectively, compared to DC SIGN
pSiNP marmosets (Figure 6).
pSiNP were detected within the liver, heart, lungs, and
kidneys of the marmosets, with few detectable clusters present
in the spleen (Figure S5). DC SIGN pSiNP marmoset lungs
showed aggregates ranging from 1 to 10 μm in size and were
more dispersed throughout the tissue compared to the isotype
pSiNP marmosets (≤8 μm). Ten μm clusters in livers from
pSiNP DC SIGN pSiNP marmoset could be seen, with
isotype pSiNP marmoset clusters generally smaller (≤4.5 μm).
DISCUSSION
In this study, DC targeted pSiNP were functionalized with
anti CD11c or anti DC SIGN antibodies to investigate
biodistribution in vivo. The nanoparticles, <200 nm in size
and functionalized with a semicarbazide linker, allowed for the
direct conjugation of antibody and fluorescent dye to their
surface. We have comprehensively characterized these pSiNP
recently in Cifuentes Rius et al.12 As DC play a major role in
both immunostimulation and immunosuppression within the
immune system, they are the most potent of the antigen
presenting cells and are responsible for the phagocytosis and
presentation of foreign peptides as well as the maintenance of
immunological self tolerance. Foreign peptides are processed
and presented on MHC classes I and II which bind
complementary receptors expressed on CD8+ and CD4+ T
lymphocytes, respectively.17 If appropriate signaling occurs via
the binding of co stimulatory proteins CD80/CD86 and CD40
on DC interacting with CD28 and CD40L expressed on T
lymphocytes, an inflammatory response promotes the clonal
expansion of T lymphocytes with the aid of pro inflammatory
cytokines.18,19 Clonal expansion of antigen specific CD4+ T
cells promotes B lymphocyte differentiation into antibody
producing plasma cells, contributing to the humoral
immunity.20 However, a lack of co stimulatory marker
expression by DC may promote T cell anergy and immune
system senescence.11 These DC are termed tol DC by their
ability to induce CD4+FoxP3+ Tregs that promote immuno
logical tolerance toward foreign antigens, such as those seen in
allogeneic organ transplantation. DC are key immune cells, and
there is significant benefit to targeting them in vivo to treat
cancer, induce tolerance, and develop new vaccines. Phase 1
clinical trials utilizing DC therapy to treat metastatic renal cell
carcinoma (RCC) have been explored by Wierecky et al.21
HLA A2 binding MUC1 peptide pulsed autologous mature
DC, derived from peripheral blood monocytes, were
subcutaneously injected into patients with RCC. This study
found a proportion of patients demonstrated tumor regression
when treated with peptide pulsed DC. Intravenous delivery of
ex vivo modified tol DC, preconditioned with vitamin D3 and
IL 10, has also prolonged allogeneic kidney graft survival in
NHP.22 These methods utilized ex vivo modification of DC
Figure 5. Flow cytometric of marmoset cellular uptake of pSiNP. (A) Marmoset gating strategy of lineage negative MHC II+CD11c+ myeloid
DC. (B) Gating of monocytes (CD14), B cells (CD20), T cells (CD3), and natural killer cell (CD56) populations for flow cytometry. (C)
Splenic and peripheral blood cell populations nanoparticle uptake. A higher proportion of isotype pSiNP were phagocytosed by splenic
myeloid DC compared to DC SIGN pSiNP. (Data are presented as ΔMFI ± SEM. Isotype pSiNP n = 2, DC SIGN pSiNP n = 3, statistical
significance determined by two tailed t test, * p < 0.05).
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prior to infusion. The emerging field of nanomedicine can
bypass this modification by their targeted therapeutic delivery
mechanisms.23 We successfully targeted DC populations
within murine and NHP animal models. OVA sensitized
mice demonstrated a significant 5 fold increase in Treg,
maintained for up to 40 days postinjections. We have
established an alternative method of drug delivery to induce
Treg generation completely in vivo while reducing off targeting
effects shown by enhanced delivery with DC targeting antigen
functionalized pSiNP.
Neither mice nor NHP showed adverse reaction to
intravenous administration of pSiNP. DC targeting pSiNP in
both models showed systemic distribution to the kidneys, liver,
spleen, and lungs. Large nanoparticles (≈ 200 nm) have been
shown to aggregate in vivo by activating the intrinsic
coagulation system.24 Clot formation promotes fibrinogen
and globulin binding to nanoparticle surface, known as corona
formation.25 These proteins unfold, linking to adjacent
nanoparticles causing aggregates.26 Furthermore, nanopar
ticle induced unfolding of fibrinogen promotes macrophage
activation by Mac 1 (CD11b) binding.27 This phenomenon
could explain the observed pSiNP aggregation within some of
the tissues. Intravenous pSiNP administration in mice traveled
via the vena cava to the heart. Large pSiNP aggregates would
travel unencumbered through larger atrial and ventricular
spaces, resulting in minimal accumulation, which was
consistent in both animal models and evident from the low
organ fluorescence (Figures 1 and 4). The pulmonary
circulation offers a site of restricted movement, due to alveolar
capillaries, providing an optimal location for pSiNP aggrega
tion, indicative of increase lung fluorescence. This accumu
lation may be enhanced by the presence of pulmonary
macrophages.28 Arterial circulation carries pSiNP to the liver,
spleen, and kidneys. pSiNP uptake in the liver could be
attributed to the non specific phagocytic nature of liver Kupffer
cells,29 one of the most abundant populations of macrophages,
resulting in the increased fluorescence (Figure 1). We observed
CD11c pSiNP preferentially tracked to the spleen compared to
isotype pSiNP as well as accumulated significantly in the
kidneys compared to all other organs. These pSiNP degrade by
90% within 24 h.15 Once broken down, these nanoparticles are
renally excreted as non toxic silicic acid.30
The NHP circulation is identical to mice, with the femoral
vein traveling to the inferior vena cava via the iliac vein.
However, distribution of pSiNP was markedly different.
Marmosets displayed high levels of pSiNP accumulation
within the lungs. This phenomenon was augmented in
marmosets injected with DC SIGN pSiNP, potentially reduc
ing the levels of DC SIGN pSiNP in the liver compared to the
isotype pSiNP (Figure 4). The undiagnosed, histologically
indicative, chronic lung disease in the marmosets (average age
13 years) compared to juvenile (6−8 weeks) mice, may explain
this finding. Splenic deposition was also different compared to
the mice. Isotype pSiNP accumulated in the spleen more than
the DC SIGN pSiNP. In accordance with the murine model,
kidney fluorescence intensity was significantly higher in DC
targeting pSiNP marmosets. Urine analysis showed that
although marmosets had a larger accumulation of DC SIGN
pSiNP within the kidneys, isotype pSiNP marmosets secreted
7 fold higher silicon concentrations, suggesting prolonged DC
SIGN pSiNP retention.
Cytometric analysis of murine and marmoset splenic DC
subsets reflected the total splenic fluorescence. CD11c pSiNP
mice had significantly greater fluorescence within the spleens
and significantly higher uptake by lineage negative, MHC
CII+CD4+ and CD8α+ conventional DC populations. CD4+
and CD8α+ DC had 9 fold and 31 fold higher fluorescence
intensities in CD11c pSiNP mice, respectively, highlighting the
importance of nanoparticle functionalization with antibodies to
preferentially target some of the least abundant cells. A higher
concentration of CD11c pSiNP in the spleen increases the
chance of non specific uptake, indicated by CD11c pSiNP
fluorescence in CD11b+CD11b− macrophages (Figure 2). The
uptake of pSiNP within CD11c+ blood DC was significantly
reduced compared to the spleen with little fluorescence
observed. Blood CD11b+ macrophages were more positive
for isotype pSiNP compared to CD11c pSiNP, potentially due
to the increased targeting and uptake of CD11c pSiNP by DC,
resulting in fewer circulating CD11c pSiNP remaining for
macrophage phagocytosis. Confocal microscopy of the spleen
showed that CD11c pSiNP were more abundant and highly
distributed throughout, compared to isotype pSiNP (Figure
S2).
pSiNP tracking to marmoset splenic myeloid DC produced
contrary results. Isotype pSiNP were phagocytosed 3.5 fold
more by the lineage negative, MHC CII+CD11c+ myeloid DC,
while DC SIGN pSiNP were taken up predominately by
CD14+ monocytes. One DC SIGN pSiNP marmoset showed
a high level of pSiNP uptake by blood CD11c+ DC. This
Figure 6. Isotype pSiNP are secreted more readily than DC SIGN
pSiNP in NHP. The pSiNP injected into the marmosets were
produced from wafers doped with boron to produce optimal
resistivity for pSiNP etching. Due to this process, silicon and
boron are the two major degradation products of the pSiNP and
can hence be used to measure particle secretion. Marmosets
injected with DC SIGN pSiNP had an approximately 7 fold and
10 fold lower concentration of silicon and boron in their urine,
respectively. (Data are representative of mean ± SD, n = 2 (isotype
pSiNP) n = 3 (DC SIGN pSINP). Statistical significance was
determined by two tailed t test, **** p < 0.0001).
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particular marmoset also displayed minimal fluorescence in the
lungs compared to the other two injected with DC SIGN
pSiNP. Since pSiNP were not trapped within the pulmonary
circulation in that marmoset, they could remain in the
circulation until they reached the spleen. The remaining two
DC SIGN pSiNP marmosets had significantly higher lung
accumulation of pSiNP, which would decrease circulating
mass. Primate histology revealed chronic lung damage and
inflammation, best characterized as chronic airways disease,
potentially due to their age. The pathology seen in the lung
may have promoted alveolar macrophage recruitment,31,32
resulting in a higher degree of non specific phagocytosis of
pSiNP. Alternatively, pulmonary DC within the lungs may
have been targeted by the particles.
The different tracking ability of DC targeting pSiNP in
murine and NHP models may also be explained by the
difference in targeting antigens and animal species. These data
showed that CD11c pSiNP promoted DC specific targeting to
a greater extent than DC SIGN pSiNP. Murine DC SIGN was
not utilized due to its expression on only CD4+ conventional
DC as well as placmacytoid pre DC lineages.33 Therefore,
CD11c was more analogous to human DC SIGN, being
expressed on only murine myeloid DC lineages. We have also
established the use of this cross reactive human DC SIGN
antibody clone to classify marmoset monocyte derived DC.34
Tol DC lack the necessary co stimulatory markers required
for naiv̈e T cell activation. Instead, tol DC differentiate naiv̈e
T cells into Treg or enhance the function of pre existing Treg.
Rapamycin induced selective expansion of murine
CD4+CD25+FoxP3+ Treg has been well documented by
Battaglia et al.35 Upon repeated stimulation with the OVA
protein on days 33, 47, and 61, the rapamycin and OVA323−339
peptide preconditioned DC would continue to phagocytose
and process the OVA protein for continued promotion of the
discrete pool of OVA reactive regulatory T cells. OVA
sensitized CD11c pSiNP (rapamycin + OVA323−339) mice
showed a significantly (5 fold) higher level of Treg compared
to the mice treated with i.v. rapamycin or isotype pSiNP. This
finding demonstrates the importance of nanoparticle function
alization with cell targeting antibodies. We have expanded on
our in vitro work where we induced tol DC with rapamycin
loaded pSiNP15 by promoting Treg expansion completely in
vivo. Future experiments utilizing these pSiNP should explore
longer time points to follow Treg fate. We previously
demonstrated the ability to produce camptothecin loaded
silicon nanoparticles, nanodiscs, and silica nanopills for the
targeted killing of neuroblastoma cancer cells.36−38 We have
now explored the potential of these pSiNP within a transplant
immunology setting. Translation of this protocol into a
transplantation model to induce graft tolerance without ex
vivo DC modification would be highly beneficial in exploring
the full extent of these nanoparticles.
Pathological changes, potentially due to age related illness,
may have resulted in the high pSiNP tracking variability within
the DC SIGN pSiNP animal test group, potentially skewing
the in vivo tracking abilities and is a main limitation within this
study. The lack of a completely identical targeting antigen
between the murine and NHP animal models also made it
difficult to compare pSiNP uptake between the two species.
Potential future directions include functionalizing pSiNP with
marmoset reactive CD11c antibody, identifying if this
promotes DC uptake within the spleen. Younger marmosets
should also be utilized for these experiments, as it was seen that
one of the DC SIGN pSiNP marmosets did display tracking
abilities to both splenic and blood DC in vivo, suggesting a
potentially highly beneficial method for targeting both
populations of DC.
CONCLUSION
In conclusion, pSiNP displaying DC targeting mAb were well
tolerated in mice and in NHP. The animals showed no adverse
side effects or embolus formation from particle aggregation.
Effective targeting to blood and tissue DC was demonstrated.
pSiNP loaded with rapamycin, targeting CD11c promoted the
generation of Treg in vivo without the more commonly used
preliminary ex vivo modification of DC. An unexpected and
interesting finding was the enhanced kidney targeting ability of
DC targeting pSiNP, demonstrating a significantly higher renal
tracking capability in murine and NHP models, compared to
isotype pSiNP. Identifying this enhanced pSiNP tracking to
the kidneys offers a potential route to treat rare conditions
such as Fanconi syndrome, cystinuria, and even renal cell
cancer. This is enhanced by the ability of pSiNP to be loaded
with a variety of medications, chemotherapeutics, or even
genomic payloads, providing a more localized, targeted
delivery. In conjunction with our recent findings, that pSiNP
can modify DC function in vitro, this study provides further in
vivo validation for the potential of targeted nanomedicine for
future drug delivery in transplantation and other immune
mediated diseases.
MATERIALS AND METHODS
Mice. Male C57BL/6 mice 7−8 weeks old were purchased from
Animal Resources Center, Western Australia. Mice received intra
venous (i.v.) injections of pSiNP (20 mg/kg) coated with purified
Armenian hamster isotype control monoclonal antibody (mAb) (BD
Biosciences, California, USA. Clone G94−56) or purified Hamster
antimouse CD11c mAb (BD Biosciences. Clone HL3). Animals were
imaged at 1, 6, 12, and 24 h. Mice were maintained in the University
of Adelaide Animal Facility in accordance with Australian animal
ethics guidelines, applications 20123 and 31951.
Marmosets. Common marmoset (Callithrix jacchus) monkeys
were housed at The Queen Elizabeth Hospital Animal house.
Marmosets received i.v. injections via left femoral vein, of pSiNP
(20 mg/kg) coated in purified isotype control (eBioscience,
California, USA, Clone eBMG2b) or DC SIGN mAb (BD
Biosciences, Clone DCN46). Animals were euthanized 24 h post
injection. Prior to the autopsy, marmosets were imaged to obtain a
topographic distribution of pSiNP. Marmosets were maintained at the
Queen Elizabeth Hospital Animal Facility in accordance with the
NHMRC Australian guidelines for the holding and use of non human
primates for medical research. CALHN animal ethics committee
approval number 55 15.
Immunization Protocol. C57BL/6 mice immunization protocol
was adapted from Maldonado et al.39 Mice were subcutaneously
injected with 100 μg of OVA protein (Grade V, Sigma. Missouri,
USA) admixed 1:1 (v/v) in saline and Alhydrogel adjuvant
(InvivoGen, California, USA), to a final volume of 100 μL on days
0, 14, and 28. Concurrently, mice received a 100 μL i.v. injection of
saline, free rapamycin (fRapamycin, 1 mg/kg), 100 μg fluorescently
labeled free OVA323−339 peptide (FITC βAla ISQAVHAAHAEI
NEAGR OH, Auspep, Victoria, Australia) (fOVA) and fRapamycin,
or isotype or CD11c pSiNP loaded with rapamycin and/or
OVA323−339. Challenges of 100 μg of OVA protein were given on
days 33, 47, and 61 subcutaneously. Mice were humanely euthanized
on day 68.
Preparation of pSiNP. pSiNP were prepared as previously
described.15 Silicon wafers were electrochemically etched and
polished in aqueous hydrofluoric acid. The porous layer was fractured
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In conclusion, we have demonstrated the ability of DC-SIGN pSiNP to track to DC populations in vitro. 
We then explored the effect rapamycin loaded pSiNP would have on DC phenotype by identify the 
maturation resistance characteristic of DC preconditioned with rapamycin. Next, we demonstrated the 
poor allogeneic stimulatory capacity of these DC in vitro, utilising mixed lymphocyte reactions. In vivo, 
we concluded that CD11c functionalised pSiNP had significantly enhanced tracking ability to splenic 
DC population. Within the non-human primates, age related illnesses possibly skewed the full tracking 
potential of these DC targeting pSiNP, showing high levels of accumulation within the lungs of the 
animals. This was one of the major limitation within this research. With a pre-existing lung condition, 
it is difficult to identify the metabolism of DC-SIGN coated pSiNP accurately within the non-human 
promote model. A benefit of exploring the pSiNP tracking in animals with a lung pathology is that it 
did highlight the enhanced pulmonary targeting of the nanoparticles within this setting. This offers an 
alternative use of these nanoparticle in the treatment of chronic obstructive pulmonary disease (COPD). 
Due to the variation of tracking within the DC-SIGN pSiNP marmosets, it definitely warrants repetition 
in younger, healthier animals to truly highly their benefit. In vivo functional tests of rapamycin loaded 
pSiNP successfully promoted regulatory T-cell generation when specifically targeting DC.  However, 
histological sections also identified large aggregates of nanoparticles deposited within some of the 
tissues, including the kidney and liver. Translating this into a human therapy could poses a potential 
problem with the chance of the particles aggregating, leading to the development of an emboli and 
potentially death. In vitro studies with these pSiNP should be carried out to identify potential factors 
that can inhibit the internal aggregation seen in vivo. This may be as simple as resuspending the pSiNP 
in a heparinised saline before i.v. injection or a physical coating of aspirin over the pSiNP to prevent 
platelet activation and inevitably the coagulation cascade. The studies performed here, highlight the 
importance of nanoparticles functionalisation for specific in vivo cell targeting. Future experiments 
should explore the functionalisation of pSiNP with alternative targeting antigens, exploring the full 
ability of these nanoparticles to deliver drugs, peptide or genomic fragments to multiple cell types 
within the body. 
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Table S1. Antibodies used for in vitro pSiNP targeting. 
Antigen Fluorophore Clone Ig Class Manufacturer 
Lineage 
     CD2 
     CD3 
     CD14 
     CD16 
     CD19 
     CD56 

















HLA-DR Pe-Cy7 G46-6 m IgG2a BD Biosciences 
CD11c APC S-HCL-3 m IgG2b eBioscience 
BDCA-2 
(CD303) 




Table S2. Antibodies used for phenotyping of monocyte-derived DC. 
Antigen Fluorophore Clone Ig Class Manufacturer 
HLA-ABC APC W6/32 m IgG2a eBioscience 
HLA-DR APC L243 m IgG2a Biolegend 
CD11c 
APC 3.9 m IgG1 
eBioscience 
PE S-HCL-3 m IgG2b 
CD14 PE 61D3 m IgG1 BD Biosciences 
CD40 
APC 
5C3 m IgG1 eBioscience 
e450 
CD80 FITC MAB104 m IgG1 Beckman Coulter 
CD83 FITC HB15e m IgG1 eBioscience 
CD86 Alexa Fluor® 488 IT2.2 m IgG2b Biolegend 






Figure S1 (A-C). Top view, front view and side view transmission electron micrographs of individual 
pSiNP. Intermittent light and dark regions indicate nanoparticle pores, scale bar represents 100 nm. 
DLS calculated particle mean size was 160 ± 4 nm. (D). Nanoparticle breakdown kinetics obtained by 
ICP-MS analysis of elemental silicon. Ninety percent of the pSiNP were broken down within the first 






Figure S2. DC-SIGN expression of monocyte-derived DC treated with functionalised pSiNP. DC 
cultured with DC-SIGN pSiNP (Blue shaded) showed decreased DC-SIGN surface expression in a time 
and dose dependant manner due to the competitive binding of the pSiNP for the same receptor epitope, 
preventing DC-SIGN-PE from binding. DC cultured with Isotype pSiNP (Black line) continued to have 
DC-SIGN receptor expression > 96% indicating that pSiNP functionalisation with DC-SIGN allowed 
for specific receptor mediated binding. Dashed line represents unstained control. Histograms show MFI 












SUPPLEMENTARY INFORMATION 2 
MURINE AND NON-HUMAN PRIMATE DENDRITIC CELL TARGETING 





Figure S1. Kidneys accumulate the higher proportion of fluorescent pSiNP in mice. (A) 
Topographical distribution of fluorescent pSiNP over 1, 6, 12 and 24 h indicated by blue colour. High 
level of accumulation was seen in the kidneys at 1 h which dissipated at 24 h. (B) Time course tracking 
experiments indicated that CD11c pSiNP tracked to the kidneys, liver, spleen and lungs with minimal 
detection in the heart. Isotype pSiNP tracked predominantly to the kidneys and liver with low level 
detection within the spleen, lungs and heart of mice. (Data are represented as mean ± SD, n = 3 per 





Figure S2. Murine splenic DC preferentially uptake CD11c pSiNP in vivo. Time course uptake of 
pSiNP by mice shows that CD11c pSiNP are taken up more readily over isotype pSiNP by CD4+ and 
CD8α+ splenic DC at 6 h. Data are presented as delta (Δ) MFI ± SD, normalised to the baseline 





Figure S3. Fluorescently labelled antibodies (Ab) showed markedly different biodistribution in 
the absence of pSiNP. (A) Individual organs taken from the mice at 24 h post injection (i.v.) with 
fluorescent Ab. Heat map (red to yellow) indicates presence of antibody. Non-targeting isotype-Ab 
shows systemic distribution to all major organs. (B) Quantification of total fluorescence as radiant 
efficiencies (RE) of each of the organs at 24 h. Kidneys expressed the highest accumulation of 
antibodies with the spleen showing no significant uptake of CD11c-Ab, contrary to CD11c-pSiNP. (C) 
Quantification of the mean fluorescence intensity (MFI), representative of Ab accumulation, within 
splenic and blood DC and macrophage populations. No significantly increased detectable levels of 
antibody fluorophore was seen in any of the conventional DC populations in mice injected with either 
isotype or CD11c-Ab. (Data is represented as mean RE or ΔMFI ± SD, n = 3 per group, significance 





Figure S4. CD11c pSiNP track to splenic DC in mice. (A) General histology of mouse organs, 
haematoxylin and eosin (H&E). Arrows in CD11c pSiNP liver and isotype pSiNP spleen indicate large 
brown pSiNP aggregates ranging up to 8 μm in diameter (24 h post injection, scale bar = 100 μm). (B) 
Immunofluorescent staining of spleens from mice injected with isotype or CD11c pSiNP (blue) co-
stained with MHC II (green) and CD11c (red). The spleen displayed a higher level of CD11c pSiNP 
distribution compared to isotype pSiNP control mice (scale bar = 100 μm). (C) Magnified section of 
spleen from a CD11c pSiNP mouse showing co-localised staining of CD11c, MHC II and pSiNP (scale 






Figure S5. Histology shows aggregates of pSiNP within tissue. H&E histological staining showed 
that a majority of the marmosets had lung tissue with increased compliance and destruction of the 
alveolar walls, consistent with chronic lung damage. Marmoset organ histology, arrows indicating 
aggregates of pSiNP within the liver, heart lungs and kidneys (scale bar = 100 μm). CD11c pSiNP 
aggregated in the lungs ranged from 1 - 10 µm and highly dispersed throughout the tissue compared to 
isotype pSiNP. Within the liver, isotype pSiNP were smaller (≤ 4.5 µm) compared to CD11c pSiNP. 
 
Table S1. Murine antibodies used in this study. 
Antigen Fluorophore Clone Ig Class Manufacturer 
     









     




FITC NIMR-4 eBioscience 
CD4 






CD8α Pacific Blue 53-6.7 IgG2a BioLegend 





PerCP-Cy5.5 N418 eBioscience 
CD25 PE 7D4 IgM Miltenyi Biotec 






Table S2. Marmoset antibodies used in this study. 
Antigen Fluorophore Clone Ig Class Manufacturer 
     









     
MHC Class II  
(HLA-DR) 
PE-Cy7 L243 IgG2a BD Biosciences 
CD11c PE S-HCL-3 IgG2b BD Biosciences 
DC-SIGN (CD209) Purified DCN46 IgG2b BD Biosciences 
 
